INDEPENDENT TRUST FINANCING FACILITY

APPLICATION

Name of Trust:	South Tyneside NHS Foundation Trust
Amount Proposed:	£9,500,000
Date of application:	02 May 2014
Former Strategic Health Authority:	North East
Main Commissioners: (2013 (£'000)	B) South Tyneside PCT £120,885 55.58% Sunderland Teaching PCT £42,469 19.53% Gateshead PCT £37,515 17.25% North East SHA £4,780 2.20% Gateshead Health NHS FT £1,522 0.70% Others £10,308 4.74% Total Income £217,479 100.00%
Existing Loans (Finance Leases) Total Existing: Amounts Proposed: Total:	Limit Drawn Maturity Rate £21,000 £21,000 N/A N/A £21,000 £21,000 A A £9,500,000 £9,521,000 36.94% Tier 1
Purpose of new loan(s):	Integrated Care Services Hub
Term of new loan(s):	10 Years
Repayment programme:	Equal instalments of principal
Interest rate:	National Loan Fund Rate currently 2.01%
Fees:	Nil
Security/Covenants	Negative pledge
Estimated Debt Capacity: Long Term (2.5x debt service:revenu Tier Working Capital (30 days OpEx)	1 £25,775,967 Beds: 417 £17,866,816
Date of Authorisation:	01/01/05 Trust Type: Acute and specialist trust
Monitor Published Rating:	Finance4GovernanceNo evident concerns
Care Quality Commission Rating	Meets all standards
Reference Cost Index (2010/11)	100 (MFF adjusted) 94 (Non-adjusted)
Ratios: Minimum dividend cover Minimum interest cover Minimum debt service cover Maximum debt service / net revenue Debt / net assets	Required (Tier 1) Projected (max) >1x 2.16 >3x 32.42 >2x 5.43 <2.5%

South Tyneside NHS Foundation Trust ("South Tyneside")

Covering Note

Introduction

South Tyneside is currently tendering for a ten year contract from South Tyneside Council to provide an Integrated Care Services Hub to support the development of an integrated care delivery plan for South Tyneside to deal with increased demand for adult care services resulting from an ageing demographic. To support delivery of this contract the Trust would need to borrow £9.5 million repayable over the life of the contract.

The Local Authority's strategic aims for the Hub are to improve range, quality and coordination of services including Residential and Nursing care, Respite, Reablement, Day Services, Information and Advice, Carers Services and Care Management. In line with these goals, South Tyneside's plans for the Hub will deliver a number of key outcomes supporting demand management of its own secondary care services including:

- Reducing inappropriate hospital and residential care admissions
- · Providing better support to people with dementia in the community
- · Enabling people to live in the community for longer

South Tyneside currently provides a range of services locally, including both hospital and community services. It sees this as a strategic opportunity to use core organisational and professional skills, both as a discreet provider and an added value service integrator, to address rising demand whilst improving care for older people. It will be partnering with Age UK for the provision of some of the less clinically based support.

The Trust has prepared a comprehensive application which is attached.

Summary Overview

South Tyneside is a relatively small acute Trust that doubled in size in 2011through the acquisition of community services. Over the last three years the integration process coupled with national pressures on revenues has resulted in a fall in EBITDA from 7% to just under 4%, whilst liquidity has dropped from 40 days to 15 days through increasing creditors to maintain free cash at around £15mn. Pay costs are 10% higher than the norm which may reflect both the small size of the Trust's acute activities and the recent integration of community services. Recognising the need for transformation, the Trust has engaged PwC on a performance related programme ("Perform") to help identify future cost savings and maintain CIPs at around 4-5%.

The proposed Hub will add to the integration of South Tyneside's community services and can almost be looked at as a standalone project assuming that the cash flows have been costed to generate a surplus, and are acceptable to South Tyneside Council. Nevertheless it should be noted that the building is depreciated over a 50 year life in the tender, not the 10 year contract life, and so there will be a net cash requirement to service the debt repayments over the term, and the benefit of a residual interest in the building at the end of the contract to support contract renewal.

It is difficult to predict how successful the Trust will be in continuing to deal with current financial pressures and the need to achieve a demanding CIP programme, but winning the tender will assist in diversifying income into a area to which it has already committed, namely community services, and will assist in strengthening the Trust's presence in this sector. There are also sensible arguments in respect of being more in control of demand management strategies for the Trust's own secondary care provision. There are also close links between the Trust and South Tyneside Council with common non-executive members.

Recommendation

On the face of it, the Trust can afford the debt service of the loan on historical cash flows, and the contract is priced to include interest costs and an element of the principal repayments through depreciation. The loan term of ten years is prudent in view of the contract term but, on the assumption that the building can be used to deliver community healthcare beyond the end of the contract, could always be extended in extremis. So although not entirely neutral, the investment is largely covered by the contract terms and will put the Trust in a favourable position to rebid the contract in due course.

Accepting that the Trust has financial pressures like many, this is a positive opportunity and should be supported. The loan is recommended for approval.

NR/30.04.14



NHS Foundation Trust

15 April 2014

Mr N Rose

4th Floor

Harton Wing South Tyneside District Hospital Harton Lane South Shields Tyne & Wear NE34 OPL Tel: 0191 4041000 Ext. 4006 Direct Dial: 0191 2024006 Facsimile: 0191 4279908 e-mail: <u>Mike.Robson@stft.nhs.uk</u>

Skipton House 80 London Road LONDON SE1 6LH

Independent Trust Finance Facility

Dear Mr Rose

Independent Trust Financing Facility – Application for Loan Finance

South Tyneside NHS Foundation Trust wish to apply for a loan to finance a new integrated care services hub details of which are as follows:

Scheme Loan Application Repayment Period Estimated interest rate Integrated Care Services Hub £9.5 million 10 years 2.91% based upon April 2014 rates

1. Introduction

In September 2013 South Tyneside Council issued notification that it wished to commission an integrated care services hub and invited expressions of interest for the provision of this facility. The closing date for the invitation to submit the final tender is 24 April 2014 and it is expected that the Contract will be fully signed and the agreement in place with the successful bidder by 28 July 2014.

The development of integrated care delivery in South Tyneside is set against the national background of an ageing demographic, increased demand for adult care services and significant budgetary pressures in the public sector.

Between 2007 and 2011 the number of people diagnosed with dementia in South Tyneside rose from 800 to over 1,100. This rate of increase is steeper than neighbouring districts, the regional and national rates, and from an already higher prevalence rate. It is estimated that the number of people with dementia will increase 14% further by 2020 and 46% by 2030.

Whilst these trends present some significant challenges to our community there is an ambition and determination in the Council and amongst local partners to seize the opportunity to transform the way health and social care services are delivered.

This will require focus in a number of key areas; prevention and early intervention, supporting people with long term conditions in their own homes, and tailoring care to meet a person's needs as they change over time. The commissioning of the Hub is a significant step that not only brings together a range of services in one place but for the first time will enable true "end to end" service integration.

The Trust provides a comprehensive range of services locally, including both hospital and community services. In the future our strategic direction as an organisation will see us making use of our core organisational and professional skills, both as a discreet provider and an added value service integrator, to address rising demand whilst improving care for older people.

The Hub will provide a range of high-quality services to adults, primarily older people, in South Tyneside. It will directly deliver a range of residential and nursing care services, whilst providing a high quality environment for a range of health and social care partners to deliver complementary services from one facility fully embodying South Tyneside Council's vision for integrated care.

The model includes care, support, information and advice, to meet a wider spectrum of care needs than has traditionally been available within one facility. The Hub provides a more integrated form of service provision than the traditional residential and nursing care services currently available within South Tyneside, incorporating a range of services and facilitating easy transition in, out, and between these services as an individual's care needs change.

An illustration of the range of services to be provided by the Hub, along with links to other complimentary services is shown in the diagram below.





Links to Wider Services

Integrated Pathways

4

The core services to be provided from the Hub are:

Reablement services (short stay beds)

The Local Authority is planning to relocate Perth Green Reablement services to the Hub – with the provision of 30 reablement beds.

Time to Think (TTT) (short stay beds)

There are 6 TTT beds identified within the Hub. These can be used to step down from hospital care or step up care from the community, for a short length of stay (up to 6 weeks). This service will ensure hospital admission is avoided, where it is not appropriate and release hospital beds earlier.

Respite beds (short stay beds)

There are currently no "planned" respite beds available in the Borough. During our consultation with key stakeholders this was flagged as a major issue in terms of supporting carers to plan a holiday, or sometimes even going into hospital. We will provide a hotel style facility to pre book respite beds in advance.

Long Stay Residential/Nursing/Elderly Mentally Infirm/End of Life Care

It is the ambition of the Local Authority to ensure that once a person requires 24 hour care they and their family will not have to undergo the trauma of moving accommodation as their care needs change i.e. move from residential to nursing care, to EMI care, as their dementia progresses or indeed for end of their life.

This 30 bedded facility will be flexible to meet the changing needs of the service users, and care for them in a safe environment with staffing levels and skills to meet the needs of all of the residents.

South Tyneside Council will fund the services provided by the Integrated Care Services Hub facility. It is expected that this funding will be from existing available monies as they plan to close the reablement facilities at Perth Green and a 30 bed residential nursing home at Connelly House.

As noted above one of the aims of the hub is to avoid hospital admissions which would impact on the Trust's non elective income. However, commissioners are actively pursuing readmission reduction initiatives and schemes introduced within the Better Care Fund to enhance integrated working within community and social care in order to reduce emergency admissions to hospital. As a provider of both hospital and community services we are therefore uniquely placed to make a really meaningful contribution in this area.

South Tyneside NHS Foundation Trust's proposal for the hub is a purpose built and innovatively designed community and virtual resource for older people in South Tyneside. It will be located on the North Eastern boundary of the existing South Tyneside District Hospital site.

South Tyneside NHS Foundation Trust is requesting a loan of £9.5m over a 10 year period to finance the estimated cost of the build and equipment for the hub. The Board of Directors have approved the application and the Board Resolution is enclosed.

2. Financial Position

South Tyneside NHS Foundation was authorised as a NHS Foundation Trust on 1 January 2005. With effect from 1st July 2011, community health services in Gateshead, South Tyneside and Sunderland transferred to South Tyneside NHS Foundation Trust from NHS South of Tyne and Wear as part of the Government's Transforming Community Services programme.

The Trust has a consistent history of delivering financial targets having delivered underlying surpluses for every year since authorisation, excluding exceptional costs for transformational schemes and the impact of revaluations.

Financial Year	Reported Surplus/ (deficit) £000	Impairments £000	Exceptional costs (restructuring/ redundancies) £000	Underlying surplus £000
2005/06	69	51		120
2006/07	880	250		1,130
2007/08	1,768	2,090		3,858
2008/09	(518)	295	767	544
2009/10	(949)	957		8
2010/11	463	(139)		324
2011/12	1,623	(77)		1,546
2012/13	(2,641)	1,204	2,326	889
2013/14 (Forecast)	(1,889)	902	573	(414)

The transfer of Community Services in 2011 resulted in the Trust's income doubling in size from £105m in 2010/11 to £218m in 2011/12. This has presented opportunities for the Trust to integrate pathways of care for community and acute services.

Whist there is an underlying deficit forecast for 2013/14, the position includes £480k in relation to an accrual at the year end for PricewaterhouseCoopers LLP fees in relation to the "Perform" project. The investment made is on the basis that the schemes identified to date deliver savings of 5 times the cost of the fees moving into the next financial year. This is a key part of the CIP programme for 2014/15, details of which are included in section 5 below.

The Trust's future financial plans, as approved by the Board, include delivery of a £500k surplus each year.

3. Strategic Context & Background

Although a comparatively small provider of hospital services by today's standards, South Tyneside NHS Foundation Trust nonetheless is consistently ranked as one of the best by the organisations which inspect and regulate it. We ensure that patient safety and quality of care is at the forefront of our work, building on our achievements in 2013-14 which saw successful CQC inspections and multiple accreditations of achievements at service and organisational level.

As a provider of both hospital and community services the Trust is uniquely placed to make a really meaningful contribution in this area. The integration of services across health and social care is seen as a major opportunity to improve care for our population and to put in place the foundations of long term and sustainable change. There is no doubt that the current economic climate combined with increased pressure across public services means that integrated working and achieving the best we can using our collective power and responsibility will be an essential factor for the continued delivery of high quality services. We understand this and will continue to play our full part and indeed lead some of these initiatives. Particularly important will be the Trust's continued work with its partners in the development of the Better Care Fund within the three main localities that it serves and as a national pioneer in integrating health and social care and developing models of self care.

We also have long standing and well established partnership working arrangements in a number of clinical networks with other local provider Foundation Trusts. The Trust has partnered with Age UK on the Integrated Care Services Hub tender, and is identifying suitable partners for other upcoming tenders.

The Trust has no existing loans and whilst it is forecasting to have cash balances in the region of £15m at the end of 2013/14, utilisation of this cash to build the hub would restrict the Trust's ability to carry out the planned capital programme which is expected to consume all internally generated resources and would result in a reduction in the existing Continuity of Services Risk Rating of 4 to a 3 by the end of 2015/16.

4. Provision of South Tyneside Integrated Care Services Hub

Details of the proposal for the design, build and operation of the hub are included in the enclosed document.

The Trust recognises that in order to be competitive in relation to pay costs in this bid it would need to explore alternative options for provision of the service. It is therefore proposing to set up South Tyneside Integrated Care Limited (STIC Ltd), a wholly owned subsidiary of South Tyneside NHS Foundation Trust, focused on the delivery of the contract. The Hub will operate in line with our contractual requirements and that of the CQC by having robust financial, business contracting and quality assurance mechanisms to provide assurance to the STIC Ltd Board, the Trust Board and the Council.

A second Special Purpose Vehicle would be set up as a holding company to enable the organisation to be future proofed so that it could respond promptly to other to business opportunities as they arise.

In setting up a subsidiary to deliver this contract we can build the capability to bid for delivery of integrated services into other parts of the North East, exporting best practice from the Hub and importing economic benefit back to South Tyneside.

Securing this contract with the Council is strategically important for the Trust's future. It will protect existing jobs and services and create new employment opportunities. In the Hub build process we will maximise the economic and social impact for the local community using local suppliers and targeting local recruitment. We wish to be seen as a beacon for best practice in delivering care to those with dementia, at whatever stage in their journey, and we plan to work with the University of Stirling to achieve accreditation for our work in this area.

The location of the Hub within the Trust site also provides opportunities for future developments. If successful these opportunities will be explored further.

In relation to the financials, additional revenue costs associated with this contract in relation to capital costs, estates and facility costs, servicing of the debt and other indirect costs would be recharged to STIC Ltd with the Trust making a contribution to its overheads as part of the transaction. STIC Ltd would employ the staff working directly into the Hub. The Trust anticipates receiving a contribution to its overheads in the region of £0.4m from the contract. A summary of the current financial assumptions in relation to the tender can be found in the supporting papers.

The tender value for the contract has been set based upon ensuring that STIC Ltd has sufficient income to meet all of its direct costs as well as those costs recharged by the Trust.

Based upon the information available within the Invitation to Submit Final Tenders, the inflator will be a maximum of a 1% inflationary increase from year 2 onwards. A correcting calculation will be made at years 4 and 8, if necessary, to account for actual CPI inflation.

The initial contract for the provision of the Hub is for a period of 10 years. In the event that the Trust was unsuccessful in securing the contract beyond that period the following options are available for the use of the building:

- Lease the building to the new provider ensuring all costs recovered
- Review the market for options for expanding into private nursing and residential facilities thereby creating new income streams
- Utilise the building as a centre of excellence for older people for the Trust, enhancing current facilities for privacy & dignity, promoting independence and providing a dementia friendly environment. This would enable other clinical services located in old, outlying buildings to be consolidated onto

the main hospital site enabling a more efficient service and reducing running costs from demolition of the old stock of buildings.

• Utilise the building for other purposes to enable older, less efficient accommodation to be vacated and demolished thereby reducing running costs (the Trust has a number of old, red brick buildings in use that are inefficient to occupy).

5. Transformation and CIP

The Trust has a strong track record of successful delivery of cost improvement targets since it became a Foundation Trust, evidenced in the table below.

Financial Year	Target £m	Delivery £m
2007/08	2.8	3.1
2008/09	4.3	4.5
2009/10	3.4	2.9
2010/11	3.3	3.8
2011/12	4.4	5.1
2012/13	10.6	10.2
2013/14 (projected)	12.5	11.2

As noted in section 2 the transfer of community services in 2011/12 resulted in income doubling in size. As a consequence of this the cost improvement plan targets have more than doubled and the target has not been met for the last two years largely due to the factors detailed below.

In addition to other planned schemes, work commenced in 2012/13 on the clinical restructure to streamline acute and community pathways of care and a comprehensive review of admin and clerical staff was undertaken with PricewaterhouseCoopers LLP. Work on these areas, along with a review of nursing and other corporate areas continued into 2013/14.

The restructures and staffing reviews were time consuming due to the process involved. Anticipated savings were identified from reductions in the number of staff employed and regrading of staff in some areas, however, a number of the affected staff were entitled to pay protection which reduced the amount that could be taken to CIP in both years. This protection will expire after 4 years for those staff under the age of 50 but will remain for those over 50 until they terminate their employment.

The Trust was faced with a number of challenges leading into 2013/14 due to the changes to Commissioners from NHS Reforms. Development of Patient Level Information Costing Systems and a review of Service Level Agreements with other Foundation Trusts were slower than expected as the Trust focused on securing all income streams in contracts with the new Commissioners in 2013/14.

As part of the rationalisation of the estate strategy the Trust purchased new office accommodation in 2012/13. Staff were moved from other leased premises into the new property to reduce rental costs. One of the CIP schemes in 2013/14 was to carry out work on rebasing of estates costs, however, this has been delayed due to availability of resource from NHS Property Services to progress the work.

The above factors resulted in slippage against these CIP schemes in to 2014/15

Of the forecast £11.2m CIP achieved for 2013/14, approximately 66% has been achieved on a recurrent basis. Progress against the target is reviewed by both the Financial Risk Management Group and the Transformation Board to ensure that savings are delivered on a recurrent basis wherever possible.

We have been faced with a very significant financial target to achieve a recurrent cost improvement plan approaching £15m in 2014/15. However, cost reductions of this scale cannot be achieved by simply doing more of the same.

To meet these challenges the Trust has implemented a major programme of change and modernisation in recent years. Our 'Choose Change -Driving Transformation Forward' programme has led to some very important strategic reshaping of services. Over the past two years we have looked at all aspects of how we deliver care, at how we organise our resources to support that care delivery and at the business systems and processes that underpin this important work. This has led to a new way of organising our staff teams into pathways of care supported by new working arrangements.

The Board now meets as a whole quarterly as a Transformation Board to review progress on the cost improvement programme and has overseen some really fundamental changes to the way we do things which have been identified by field staff delivering services. The Programme Management Office (PMO) team have been key to the success of the programme of transformation. The PMO ensures all projects in the pipeline demonstrate clarity on the size, source and allocation of any potential savings. They then consolidate this information and present a performance dashboard to Transformation Board that highlights exceptions, such that Transformation Board can gain a level of assurance that the programme remains on target overall. In addition to this, to ensure that the programme does not have an adverse impact on quality of care, we have ensured extensive clinical involvement in schemes throughout their development and implementation.

The Trust has been working with PricewaterhouseCoopers LLP during the year on the development of the "Perform" methodology which will continue to be implemented as a major element of our transformation programme. Essentially, Perform optimises what managers in the Trust do, how they do it and provides them with the tools / techniques to improve performance. It provides managers and their teams a framework that helps them and their teams act and behave differently and become equipped with capabilities and support needed to channel resources effectively and efficiently towards securing the Trusts vision and strategic objectives. Work carried out with pilots during 2013/14 has demonstrated that Perform works and provided some confidence that it can help the Trust release between 15 - 20% of its capacity to be used to either generate additional income or reduce operating costs.

However, it is not just about reducing cost or increasing revenue; it is also about improving productivity, operational control, quality of service provided and importantly, employee engagement. Employees in the areas where Perform has been deployed as a way of working have embraced it and find it easier to do their jobs effectively. The Trust's experience of Perform so far has shown that it engages people, makes improvements quickly with no IT, acts as enabler to change and delivers organisation outcomes for the Trust such as reduced cost or increased income. For these reasons, Perform will be at the heart of our approach to driving up performance and quality of our services during 2014/15 and beyond. Further details on the roll out of Perform and the potential benefits are included in the supporting documentation.

We also have long standing and well established partnership working arrangements in a number of clinical networks with other local provider Foundation Trusts. The majority of our services are now closely linked with other providers to ensure that we each meet high standards of care, that services are safe and sustainable and that we work collaboratively to design care pathways for the future that are fit for purpose and provide our patients with equity of access to services provided in the best place to meet their needs by the right expert staff to achieve the best outcome for them. Whilst these partnerships are with a wide range of Trusts our principle collaboration has been with the two provider foundation Trusts South of Tyne in Gateshead and Sunderland. This work programme known locally as the Bigger Picture has seen a number of very important initiatives to secure local services of the right quality that are sustainable and affordable out into the future. Notably in 2013/14 we consolidated an innovative partnership model of stroke services built on a telemedicine model allowing patients to be diagnosed and treated locally without having to travel out of their area. This was enhanced by the provision of services across the work for Transient Ischaemic Attacks which had previously not been available to that extent. This is a good example of how by working in partnership we have been able to secure and extend local provision which otherwise would not have been possible.

Also during 2013/14 we implemented planned changes to pathology services as part of this programme with services in Sunderland transferring to a centralised model with a state of the art facility in Gateshead. Whilst locally each site will retain hot lab facilities for emergency and urgent tests this move will enable the joint development of pathology services that are second to none – another outstanding example of collaboration and mature partnership working. We have a number of ongoing partnership discussions of a similar nature which we expect to bear dividend in the coming year and increasingly see this networked approach as a fundamental aspect of the way we work to ensure high quality local service provision with appropriate access to specialist care.

6. Request for Funding

As demonstrated above the Trust has a proven track record of financial success.

If successful the contract to provide an integrated care services hub would be for 10 years. The hub has an estimated capital cost of £9.5m and the Trust is requesting a loan for that amount over the 10 year contract. If the Trust were unsuccessful in its application the loan would not be required. The loan would enable the Trust to retain its Continuity of Services Risk Rating of 4.

Additional revenue costs associated with this contract, including financing of it, would be recharged to STIC Ltd with the Trust receiving a contribution to its overheads as part of the transaction.

The Foundation Trust is confident that is can meet the debt service requirements associated with this loan and retain significant margins against the limits set down. This is demonstrated in the table below.

Ratios:	Limits	Projected Max
Minimum Dividend Cover (min)	>1	2.99
Minimum Interest Cover (min)	>3	30.66
Minimum Debt Service Cover (min)	>2	7.02
Maximum Debt Service to Revenue (max)	<3%	0.57
Debt/Net assets		10%

7. Summary

As a provider of both hospital and community services South Tyneside NHS Foundation Trust is uniquely placed to make a really meaningful contribution in the integration of services across health and social care.

We have an ambition to develop a centre of excellence for ageing in South Tyneside that evidences best practice, stimulates local innovation and attracts investment and the best talent. This would be an important development for the Trust also creates a growth opportunity for the Trust to replicate its delivery of integrated services into other parts of the North East.

In support of our application we have enclosed the following documentation:

- Enc 1 Proposal for the design, build and operation of South Tyneside Integrated Care Services Hub
- Enc 2 Financial Summary for the Hub
- Enc 3 South Tyneside FT Financial Information & Plan for 2013/14 to 2015/16
- Enc 4 Details of the "Perform" programme
- Enc 5 Annual Accounts for 2012/13
- Enc 6 Board Resolution for the application of the loan on 1 April 2014

Please do not hesitate to contact me if you require any further information in support of this application. I look forward to hearing from you.

Yours faithfully

p. Plake

Mike Robson Director of Finance and Corporate Governance

South Tyneside NHS Foundation Trust Annual Accounts

	2010/11 £000	2011/12 £000	2012/13 £000
Operating income	105,022	217,662	217,479
Operating expenses		(213,143)	、 ,
Operating surplus	3,176	4,519	107
Finance costs			
Finance income	79	84	82
Finance cost - financial liabilities	(16)	(12)	(9
Finance cost - unwinding of discount and change			
in discount rate on provisions	(8)	(22)	(24
PDC dividends payable	(2,768)	(2,946)	(2,797
Net finance costs	(2,713)	(2,896)	(2,748
(DEFICIT)/SURPLUS FOR THE YEAR	463	1,623	(2,641
Other comprehensive income:			
Impairments	0	0	(1,817
Revaluations	4,282	906	(
Receipt of donated assets	437	0	(
Public Dividend Capital Received in Year	0	0	267
Assets Held for Sale impaired to the revaluation reserve	0	0	(35
Other reserve movements	(122)	0	` (
TOTAL COMPREHENSIVE (EXPENSES)/INCOME FOR THE YEAR	5,060	2,529	(4,226
NON-CURRENT ASSETS			
Intangible assets	110	152	183
Property plant and equipment	88,505	90,113	88,654
Trade and other receivables	492	598	602
Total non-current assets	89,107	90,863	89,439
CURRENT ASSETS			
Inventories	1,551	1,868	2,027
Trade and other receivables	3,425	8,068	5,452
Non-current assets held for sale	383	265	230
Cash and cash equivalents	17,499	19,859	20,271
Total current assets	22,858	30,060	27,980
CURRENT LIABILITIES			
Trade and other payables	(7,477)	(14,438)	(13,147
Borrowings	(1)	(5)	(8
Provisions	(1,066)	(904)	(2,780
Other liabilities	(1,468)	(1,127)	(1,269
Total current liabilities	(10,012)	(16,474)	(17,204
NON-CURRENT LIABILITIES			
Borrowings	(25)	(20)	(13
Provisions	(638)	(612)	(611
Other liabilities - Govt Grant Reserve	(1,297)	Ó	
Total non-current liabilities	(1,960)	(632)	(624
TOTAL ASSETS EMPLOYED	99,993	103,817	99,591
TAXPAYERS' EQUITY			,
Public dividend capital	42,206	42,206	42,473
Revaluation reserve	41,398	41,653	37,510
Donated Asset Reserve	1,855	0	01,010
Income and expenditure reserve	14,534	19,958	19,608
TOTAL TAXPAYERS' EQUITY	99,993	103,817	99,59
Note: 2010/11 was restated in 2011/12 to remove donated & government			33,33

Г	2010/11	2011/12	2012/13
	£000	£000	£000
Cash flows from operating activities			
Operating surplus	3,176	4,519	107
Non-cash income and expense:			
Depreciation and amortisation	4,306	4,613	4,888
Impairments	278	130	1,235
Reversals of impairments	(417)	(207)	(31)
Loss on disposal		8	36
Transfer from the donated asset reserve	(121)	0	0
Amortisation of government grants	34	0	0
(Increase)/Decrease in Trade and Other Receivables	(70)	(3,842)	2,595
(Increase)/Decrease in Inventories	(119)	(27)	(159)
(Decrease)/increase in trade and other payables	(810)	6,280	(935)
Increase/(decrease) in other liabilities	352	(341)	142
Increase/(decrease) in provisions	(653)	(341)	1,859
Movements in operating cash flow in respect of	0	(000)	0
Transforming Community Services transaction	0	(630)	0
Other movements in operating cash flows Net cash generated from operations	411	0 10,162	(11) 9,726
Cash flows from investing activities	6,367	10,162	9,720
Interest received	76	88	81
Purchase of intangible assets	(105)	(76)	(77)
Purchase of property, plant and equipment	(6,709)	(4,797)	(6,808)
Sales of property, plant and equipment	(0,703)	(139	(0,000)
Net cash used in investing activities	(6,620)	(4,646)	(6,792)
Cash flows from financing activities	(0,020)	(4,040)	(0,101)
Public dividend capital received	0	0	267
Capital element of finance lease rental payments	2	(1)	(4)
Interest element of finance lease	(16)	(12)	(9)
PDC dividend paid	(2,384)	(3,143)	(2,776)
Net cash used in financing activities	(2,398)	(3,156)	(2,522)
Increase in cash and cash equivalents	(2,651)	2,360	412
Cash and cash equivalents at 1 April 2010/11/12	20,150	17,499	19,859
Cash and cash equivalents at 31 March 2011/12/13	17,499	19,859	20,271
RATIOS			
EBITDA Margin	7.02%	4.26%	3.80%
Surplus Margin	0.44%	4.20 % 0.75%	-1.21%
Average Return on Assets	0.777/0	1.59%	-2.60%
Current Ratio	228%	182%	163%
Cashflow Ratio (Op Cash / Depreciation + Dividend)	103%	123%	107%
Capex Ratio (Capex / Depreciation)	157%	106%	141%
Gearing (LT Liabs / Net Assets)	2%	1%	1%
Liquidity	40	20	15
Capital Service Ratio	2.7	3.1	3.1
Liquidity Rating	4	4	4
Capital Service Rating	4	4	4
Overall Rating	4	4	4

uth Tyneside NHS Foundation Trust						End
nned Income Statement for SOUTHTYNESIDE			Actual for	Plan for	Plan for	Plan for
			Year ending	Year ending	Year ending	Year endi
arating	units	sense	31-Mar-13	31-Mar-14	31-Mar-15	31-Mar-1
NHS Clinical Revenue						
NHS Community activity revenue Cost & Volume/PbR revenue, inpatient activity	£m	(+ve)		0.000	0.000	0.000
Cost & Volume/PbR revenue, inpatient activity	£m	(+ve) (+ve)		0.000	0.000	0.000
Cost & Volume/PbR revenue, community based activity	£m	(+ve)	9.196	8.269	8.178	8.089
Block Contract revenue, inpatient activity	£m	(+ve)		0.000	0.000	0.000
Block Contract revenue, outpatient activity Block Contract revenue, community based activity	£m £m	(+ve) (+ve)	96.878	0.000 83.386	0.000 82.538	0.000 81.617
Block Contract revenue, other activity	£m	(+ve)		0.000	0.000	0.000
NHS Community activity revenue, Total	£m	(+ve)	106.074	91.656	90.717	89.706
NHS Acute Activity Income Elective inpatients						
Tariff revenue	£m	(+ve)	5.119	5.324	5.265	5.207
Non-Tariff revenue	£m	(+ve)	0.194	0.125	0.124	0.122
Elective activity revenue, Total	£m		5.313	5.449	5.389	5.329
Elective day case patients (Same day)				·		
Tariff revenue	£m	(+ve)	8.318	8.194	8.104	8.015
Non-Tariff revenue	£m	(+ve)		0.027	0.026	0.026
Elective Day Case activity revenue, Total	£m		8.318	8.221	8.130	8.041
Non-Elective patients						
Tariff revenue	£m	(+ve)	33.907	30.748	30.410	30.075
Non-Tariff revenue Non-Elective activity revenue, Total	£m £m	(+ve)	1.755 35.662	0.570 31.318	0.562 30.972	0.555 30.631
Non-Elective activity revenue, i otal Outpatients	£m		33.002	31.310	30.972	30.031
Tariff revenue	£m	(+ve)	13.387	10.238	10.125	10.014
Non-Tariff revenue	£m	(+ve)	0.508	0.128	0.127	0.125
Outpatients activity revenue, Total	£m		13.895	10.366	10.252	10.139
A&E				·		
Tariff revenue	£m	(+ve)	5.644	4.997	4.942	4.888
Non-Tariff revenue	£m	(+ve)		0.000	0.000	0.000
A&E activity revenue, Total Other NHS activity	£m		5.644	4.997	4.942	4.888
Tariff revenue	£m	(+ve)	1.735	5.627	5.565	5.504
Non-Tariff revenue	£m	(+ve)	26.812	29.768	28.516	27.815
Other NHS activity revenue, Total	£m	(10)	28.547	35.395	34.081	33.319
-						
Total NHS Tariff income	£m		68.110	65.127	64.411	63.702
Total NHS Non-Tariff income	£m		29.269	30.618	29.355	28.643
NHS Acute Activity Income, Total	£m		97.379	95.745	93.766	92.346
Sub-total NHS Clinical Revenue	£m		203.453	187.401	184.482	182.051
Contract penalties or adjustments not included above NHS Clinical Revenue, Total	£m £m	(+ve)	203.453	0.000 187.401	184.482	182.051
Non Mandatory/Non protected revenue	2.00		203.433	107.401	104.402	102.05
Private patient revenue	£m	(+ve)	0.044	0.050	0.051	0.052
Other Non Mandatory/Non protected clinical revenue	£m	(+ve)	2.583	13.343	13.596	13.841
Non Mandatory/Non protected revenue, Total Other Operating Revenue	£m		2.627	13.393	13.647	13.893
Research and development revenue	£m	(+ve)	0.938	0.306	0.302	0.299
Education and training revenue	£m	(+ve)	4.843	4.205	4.205	4.205
PFI specific revenue	£m	(+ve)	0.004	0.000		
Donations received in cash & to fund Operating Expenses Grants received in cash & to fund Operating Expenses	£m £m	(+ve) (+ve)	0.024	0.000		
		(,			•	
Donations & Grants received of PPE & intangible assets (see comment)	£m	(+ve)		0.000		
Donations & Grants received of cash to buy PPE & intangible assets (see comment) Donations & Grants received of PPE & intangible assets			0.400	0.159 0.159	0.000	0.000
			0.400	0.155	0.000	0.000
Parking revenue	£m	(+ve)	0.348	0.380	0.399	0.419
Catering revenue	£m	(+ve)	0.600	0.598	0.624	0.655
Accommodation revenue Revenue from non-patient services to other bodies	£m £m	(+ve) (+ve)	0.053 1.686	0.000	0.000 1.412	0.000
Misc. other operating revenue	£m	(+ve)	1.908	1.545	1.574	1.602
Other Operating revenue, Total	£m		10.400	8.445	8.516	8.592
Operating Revenue, IFRS, Total Operating Expenses	£m		216.880	209.398	206.646	204.53
Raw Materials and Consumables Used						
Drugs	£m	(-ve)	(5.840)	(5.745)	(5.782)	(5.881
Clinical supplies	£m	(-ve)	(13.224)	(12.371)	(11.996)	(11.949
Decrease (increase) in inventories of finished goods & WIP	£m	(-ve)		0.000		
Vehicle Fuel costs (ambulance trusts)	£m	(-ve)		0.000		
Non-clinical supplies	£m	(-ve)	(1.900)	(2.161)	(2.166)	(2.118)
Raw Materials and Consumables Used, Total	£m		(20.964)	(20.277)	(19.945)	(19.949
Cost of Secondary Commissioning of mandatory services	£m	(-ve)		0.000		
Employee Expenses [was "Pay"]				·		
Employee expenses, permanent staff	£m	(-ve)	(153.856)	(148.728)	(146.891)	(145.15
Employee expenses, agency & contract staff	£m	(-ve)	(3.880)	(0.514)	(0.448)	(0.444)
Employee Expenses, Total	£m	(-ve)	(157.736)	(149.243)	(147.339)	(145.59
Research & Development expense	£m	(-ve)	(0.308)	0.000	(0.565)	(0.595
Education and training expense Consultancy expense	£m £m	(-ve) (-ve)	(0.308) (1.572)	(0.549) (0.700)	(0.565) (0.712)	(0.585 (0.746
Misc. other Operating expenses	£m	(-ve)	(27.945)	(30.372)	(29.986)	(29.563
(Increase)/decrease in Provisions, Current and Non-Current, net	£m	(+/-ve)	0.299	0.000	<u></u>	120.000
(Increase)/decrease in Impairment of receivables, Current and Non-Current, net	£m	(+/-ve)	(0.084)	0.000		
PFI operating expenses	-					
PFI unitary payment IFRIC12 revenue/(expense) adjustment	£m £m	(-ve) (+/-ve)		0.000		
Other PFI expenses	£m £m	(+/-ve) (-ve)		0.000		
	au 11					
PFI operating expenses, total	£m	(-ve)	0.000	0.000	0.000	0.000

South Tyneside NHS Foundation Trust

Planned	Income Statement for SOUTHTYNESIDE

nned Income Statement for SOUTHTYNESIDE						
			Actual for	Plan for	Plan for	Plan for
	units	sense	Year ending 31-Mar-13	Year ending 31-Mar-14	Year ending 31-Mar-15	Year endi 31-Mar-1
Depreciation and Amortisation			······	·		·····
Depreciation and Amortisation - purchased/constructed assets	£m	(-ve)	(4.705)	(4.790)	(4.791)	(4.791)
Depreciation and Amortisation - donated/granted assets Depreciation and Amortisation - owned assets	£m	(-ve)	(0.179)	(0.162) (4.953)	(0.162)	(0.162)
Depreciation and Amortisation - assets held under finance leases	£m	(-ve)	(4.884)	0.000	(4.953)	(4.953)
Depreciation and Amortisation - PFI assets	£m	(-ve)	(0.004)	0.000		
Depreciation and Amortisation, Total		(,	(4.888)	(4.953)	(4.953)	(4.953)
Impairment (Losses) / Reversals net - purchased/constructed assets	£m	(-ve)	(1.203)	0.000	<u></u>	(
Impairment (Losses) / Reversals net - donated/granted assets	£m	(-ve)	(0.002)	0.000		
Impairment (Losses) / Reversals net (on non-PFI assets)	2.00	(•c)	(1.205)	0.000	0.000	0.000
Impairment (Losses)/ Reversals net on PFI assets	£m	(-/+ve)		0.000		
Restructuring Costs	£m	(-ve)	(2.326)	0.000		
Operating Expenses excluded from EBITDA, Total	£m	(-ve)	(8.419)	(4.953)	(4.953)	(4.953)
Operating Expenses IFRS, Total			(216.729)	(206.093)	(203.500)	(201.39)
Surplus (Deficit) from Operations			0.151	3.305	3.146	3.144
Operating						
Non-Operating income						
Finance Income [for non-financial activities]		<i>(</i>				
Gain (Loss) on Financial Instruments Designated as Cash Flow Hedges	£m	(+ve)		0.000		_
Gain (Loss) on Derecognition of Available-for-Sale Financial Assets	£m	(+ve)		0.000		
Gain (Loss) on Derecognition of Non-Current Assets Not Held for Sale, Total	£m	(+ve)		0.000		ļ
Gain (Loss) on Investments & Inv.Property (NOT charitable funds)	£m	(+ve)		0.000		Ļ
Interest Income	£m	(+ve)	0.081	0.083	0.083	0.083
Dividend Income	£m	(+ve)		0.000		L
Share of profit (loss) from equity accounted Associates, Joint Ventures				,		
Share of Private Patient Income from equity accounted Associates, Joint Ventures	£m	(+ve)		0.000		
Share of non Private Patient Income from equity accounted Associates, Joint Ventur	£m	(+ve)		0.000		
Share of expenses from equity accounted Associates, Joint Ventures	£m	(-ve)		0.000		
Share of profit (loss) from equity accounted Associates, Joint Ventures, Total	£m		0.000	0.000	0.000	0.000
Finance Income [for non-financial activities], Total	£m		0.081	0.083	0.083	0.083
Other Non-Operating income	£m					
Gain/(loss) on asset disposals	£m	(+/-ve)	(0.043)	0.000		
Gain/(loss) from transfer by absorbtion	£m	(+/-ve)	,,	0.000		
Other Non-Operating income	£m	(+ve)		0.000		
Other Non-Operating income, Total	£m	. ,	(0.043)	0.000	0.000	0.000
Non-Operating income, Total	£m		0.038	0.083	0.083	0.083
Non-Operating expenses						
Finance Costs [for non-financial activities] Interest Expense Interest Expense on Overdrafts and Working Capital Facilities	£m	(-ve)		0.000		
Interest Expense on Bridging loans	£m	(-ve)		0.000		
Interest Expense on Non-commercial borrowings	£m	(-ve)		0.000		
Interest Expense on Commercial borrowings	£m	(-ve)		0.000		
Interest Expense on Finance leases (non-PFI)	£m	(-ve)	(0.009)	0.000		
Interest Expense on PFI leases & liabilities	£m	(-ve)		0.000		
Interest Expense, Total	£m	(,	(0.009)	0.000	0.000	0.000
Other Finance Costs	£m	(-ve)	(0.024)	(0.022)	(0.022)	(0.022
PDC dividend expense	£m	(-ve)	(2.797)	(2.706)	(2.706)	(2.706
Finance Costs [for non-financial activities], Total	£m	(-ve)	(2.830)	(2.728)	(2.728)	(2.728
Other Non-Operating expenses	LIII		(2.030)	(2.720)	(2.720)	(2.720
	C	(0.000		r
Non-Operating PFI costs (eg contingent rent)	£m	(-ve)		0.000	0.000	0.000
Other Non-Operating expenses (developments)	£m	(-ve)		0.000	0.000	0.000
Misc Other Non-Operating expenses	£m	(-ve)		0.000		
Other Non-Operating expenses, Total Non-Operating expenses, Total	£m £m		0.000	0.000 (2.728)	0.000 (2.728)	0.000
איזיי-סיטיונעוואַ באירבווסבס, ויטנמו	£111		(2.830)	(2.720)	(2.120)	(2.728
Surplus (Deficit) before Tax	£m		(2.641)	0.659	0.501	0.499
Income Tax (expense)/ refund	£m	(-/+ve)		0.000		L
Surplus (Deficit) After Tax	£m		(2.641)	0.659	0.501	0.499
Profit/(loss) from discontinued Operations, Net of Tax Surplus (Deficit) After Tax from Continuing Operations	£m £m	(+/-ve)	(2.641)	0.000	0.501	0.499
Sulpus (Dencir) Alter Tax non continuing operations	2.111		(2.041)	0.033	0.501	0.433
Elements of Comprehensive Income Share of comprehensive income from associates and joint ventures	£m	(+/-ve)		0.000		
Revaluation gains/(losses) of donated/granted assets straight to reval reserve	£m	(+/-ve)	0.003	0.000		
Revaluation gains/(losses) of purchased/constructed assets straight to reval reserve	£m	(+/-ve) (+/-ve)	0.180	0.000		
Revaluation gains/(losses) straight to revaluation reserve		, ,	0.183	0.000	0.000	0.000
(Impairments)/reversals of purchased/constructed assets straight to reval reserve	£m	(+/-ve)	(1.944)	0.000		
(Impairments)/reversals of donated/granted assets straight to reval reserve	£m	(+/-ve)	(0.056)	0.000		L
Impairments/(reversals) straight to revaluation reserve			(2.000)	0.000	0.000	0.000
Fair Value gains/(losses) straight to reserves	£m	(+/-ve)		0.000		
Additions/(reduction) in "Other reserves" Other recognised gains and losses	£m £m	(+/-ve) (+/-ve)		0.000		
Other recognised gains and losses Actuarial gains/(losses) on defined benefit pension schemes	£m £m	(+/-ve) (+/-ve)		0.000		
Elements of Comprehensive Income, Total		,	(1.817)	0.000	0.000	0.000
			(4.458)	0.659	0.501	0.499
Total Comprehensive Surplus/(Deficit)						204.61
Memorandum lines	c		216 010			
Memorandum lines Total Revenue	£m		216.918	209.481	206.729	
Memorandum lines Total Revenue Total Expenses	£m		(219.559)	(208.822)	(206.228)	(204.12
Memorandum lines Total Revenue						(204.120 204.530 (196.439
Memorandum lines Total Revenue Total Expenses Total Operating Revenue for EBITDA	£m £m		(219.559) 216.480	(208.822) 209.239	(206.228) 206.646	(204.1 204.5

						1
ned Income Statement for SOUTHTYNESIDE			Actual for	Plan for	Plan for	Plan for
	units	sense	Year ending 31-Mar-13	Year ending 31-Mar-14	Year ending 31-Mar-15	Year endi 31-Mar-1
Surplus (Deficit) After Tax (for FRR calculation)	£m		(2.641)	0.659	0.501	0.499
Return After Financing (for FRR calculation)	£m		0.533	0.500	0.501	0.499
OTHER INFORMATION						
Revenue Generation Programmes						
Revenue Generation, net	£m	(+/-ve)		0.000		
Cost Improvement Programmes		(,	·			<u></u>
Pay Expense savings CIP recurrent	£m	(+/-ve)	3.045	6.162	5.366	5.050
Pay Expense savings CIP non-recurrent	£m	(+/-ve)	2.638	2.654	2.547	2.377
Pay Expense savings CIP, TOTAL	£m	(+/-ve)	5.683	8.816	7.913	7.427
Drugs expense savings CIP recurrent	£m	(+/-ve)	0.015	0.207	0.229	0.202
Drugs expense savings CIP non-recurrent	£m	(+/-ve)	0.112	0.071	0.100	0.096
Drugs expense savings CIP, TOTAL	£m	(+/-ve)	0.127	0.278	0.329	0.298
Clinical Supplies expense savings CIP recurrent	£m	(+/-ve)	0.266	0.422	0.720	0.462
Clinical Supplies expense savings CIP non-recurrent	£m	(+/-ve)	0.106	0.136	0.208	0.196
Clinical Supplies expense savings CIP	£m	(+/-ve)	0.372	0.558	0.928	0.658
Non-clinical Supplies expense savings CIP recurrent	£m	(+/-ve)	0.338	0.077	0.069	0.121
Non-clinical Supplies expense savings CIP non-recurrent	£m	(+/-ve)	0.059	0.050	0.046	0.044
Non-clinical Supplies expense savings CIP	£m	(+/-ve)	0.397	0.127	0.115	0.165
Misc. Other Operating Expenses CIP recurrent	£m	(+/-ve)	2.042	2.424	1.628	1.646
Misc. Other Operating Expenses CIP non-recurrent	£m	(+/-ve)	1.609	0.331	0.532	0.496
Misc. Other Operating Expenses CIP	£m	(+/-ve)	3.651	2.756	2.160	2.142
Other expense savings CIP, recurrent	£m	(+/-ve)	0.000	0.000	0.000	0.000
Other expense savings CIP non-recurrent	£m	(+/-ve)	0.000	0.000	0.000	0.000
Other expense savings CIP	£m	(+/-ve)	0.000	0.000	0.000	0.000
Cost Improvement Programmes, Total			10.230	12.536	11.445	10.690
MEMORANDUM lines						
Private Patient Income, YTD, Total			0.044	0.050	0.051	0.052
Proxy for Patient Related Income, YTD, Total			206.080	200.794	198.129	195.944
Private Patient Income, YTD, %			0.0%	0.0%	0.0%	0.0%
PBC Calculations						
Revenue available for debt service			8.651	8.340	8.182	8.180
Planned debt Interest expense (excl Bridging loans)			-0.009	0.000	0.000	0.000
PDC dividend payable			-2.797	-2.706	-2.706	-2.706
Revenue			216.480	209.239	206.646	204.536
CIP% of Op.Exp. less PFI Exp.			4.7%	5.9%	5.5%	4.9%

South Tyneside NHS Foundation Trust

Enc 3	

anned Statement of Position for SOUTHTYNESIDE						
	units	sense	Actual at 31-Mar-13	Plan for 31-Mar-14	Plan for 31-Mar-15	Plan fo 31-Mar-1
sets						
Assets, Non-Current	_					
Intangible Assets, Net, Donated or granted Intangible Assets, Net, Purchased or created	£m £m	(+ve) (+ve)	0.183	0.000	0.079	0.025
Intangible Assets, Net	LIII	(+ve)	0.183	0.133	0.079	0.025
Property, Plant and Equipment, Net, Donated or granted	£m	(+ve)	1.732	1.698	1.501	1.313
Property, Plant and Equipment, Net, Purchased or constructed	£m	(+ve)	86.922	87.352	99.386	99.57
Property, Plant and Equipment, Net			88.654	89.050	100.887	100.88
Investment Property	£m	(+ve)		0.000	(
Investments, Non-Current, Total	£m		0.000	0.000	0.000	0.000
Deferred Tax Assets	£m	(+ve)		0.000		
Trade and Other Receivables, Non-Current						
Other Receivables, Non-Current	£m	(+ve)	0.602	0.602	0.602	0.602
Trade and Other Receivables, Net, Non-Current, Total			0.602	0.602	0.602	0.602
Prepayments, Non-Current	£m	(+ve)	0.000	0.000	0.000	0.000
Other Financial Assets, Non-Current, Total		. ,	0.000	0.000	0.000	0.000
Off balance sheet PFI assets, Non-Current, Total			0.000	0.000	0.000	0.000
Other Assets, Non-Current, Total			0.000	0.000	0.000	0.000
Assets, Non-Current, Total			89.439	89.785	101.568	101.51
Assets, Current						
Inventories	£m	(+ve)	2.028	1.825	1.825	1.825
Current Tax Receivables	£m	(+ve)	2.020	0.000	1.023	1.025
	£IIÌ	(+ve)		0.000		
Trade and Other Receivables, Current	-	(··· · ·	0.075	0.000	0.000	0.000
NHS Trade Receivables, Current, Gross	£m	(+ve)	2.375	3.000	3.000	3.000
Non NHS Trade Receivables, Current, Gross	£m	(+ve)	0.231	0.300	0.300	0.300
Other related party receivables, Gross	£m	(+ve)	0.127	0.850	0.850	0.850
Other Receivables, Current, Gross	£m	(+ve)	1.695	1.733	1.733	1.733
Impairment of Receivables, Current (for bad & doubtful debts)	£m	(-ve)	(0.232)	(0.232)	(0.232)	(0.232
Trade and Other Receivables, Net, Current, Total			4.196	5.651	5.651	5.651
Other Financial Assets, Current			·	·		·
Accrued Income	£m	(+ve)	0.111	0.142	0.142	0.142
Derivatives and embedded derivatives assets, current	£m	(+ve)		0.000		
Available for Sale financial assets	£m	(+ve)		0.000		
PDC dividend overpayment receivable	£m	(+ve)	0.017	0.000		
Deposits and Investments (illiquid or non-'safe harbour')	£m	(+ve)		0.000		
Other Financial Assets, Current	£m	(+ve)		0.000		
Other Financial Assets, Current, Total		(-)	0.128	0.142	0.142	0.142
Prepayments, Current			0.120		••••=	••••
Prepayments, Current, PFI related not lifecycle assets	6m	(+)(0)		0.000		
Prepayments, Current, PFI related for Lifecycle assets (only)	£m	(+ve)		[
	£m	(+ve)	4.400	0.000	4.400	4.400
Prepayments, Current, non-PFI related	£m	(+ve)	1.128	1.128	1.128	1.128
Prepayments, Current, Total	£m		1.128	1.128	1.128	1.128
Cash and Cash Equivalents				·		
Cash with Government Banking Service	£m	(+ve)	20.253	16.763	17.710	18.39
Cash with commercial banks and in hand	£m	(+ve)	0.018	0.000		
Deposits and Investments (liquid and 'safe harbour')	£m	(+ve)		0.000	j	
Cash and Cash Equivalents, Total	£m		20.271	16.763	17.710	18.39
Other Assets, Current						
Non-Current Assets held for sale	£m	(+ve)	0.230	0.472	0.125	
Other Assets, Current	£m	(+ve)		0.000		
Other Assets, Current, Total		. ,	0.230	0.472	0.125	0.000
Assets, Current, Total	£m		27.981	25.981	26.581	27.14
ASSETS, TOTAL	£m		117.420	115.766	128.149	128.65
bilities						
Liabilities, Current						
Interest-Bearing Borrowings, Current				r		r
Bank Overdraft	£m	(-ve)		0.000		
Drawdown in Committed Facility	£m	(-ve)		0.000		
Bridging loans, Current	£m	(-ve)		0.000		
Loans, non-commercial, Current (DH, FTFF, NLF, etc)	£m	(-ve)		0.000		
Loans, commercial, Current	£m	(-ve)		0.000		
Interest-Bearing Borrowings, Current, Total	£m		0.000	0.000	0.000	0.00
Non-Interest-Bearing Borrowings, Current	£m	(-ve)		0.000		
Deferred Income, Current	£m	(-ve)	(1.269)	(1.270)	(1.270)	(1.270
		(-ve)		0.000		
Deferred Grant Income, Current	£m	(-ve)			(0.156)	(0.162
Deferred Grant Income, Current			(2.780)	(0.151)		(0.102
Deferred Grant Income, Current Provisions, Current	£m	(-ve)	(2.780)	(0.151)	(0.100)	
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current	£m £m	(-ve) (-ve)	(2.780)	0.000	(0.1007	
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables	£m	(-ve)	(2.780)	· · · · · · · · · · · · · · · · · · ·	(0.1007	
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current	£m £m £m	(-ve) (-ve) (-ve)		0.000		
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current Trade Payables, Current	£m £m £m	(-ve) (-ve) (-ve)	(3.441)	0.000 0.000 (3.214)	(3.214)	·····
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current	£m £m £m	(-ve) (-ve) (-ve)		0.000		·····
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current Trade Payables, Current	£m £m £m	(-ve) (-ve) (-ve)	(3.441)	0.000 0.000 (3.214)	(3.214)	(5.270
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current Trade Payables, Current Other Payables, Current	£m £m £m £m	(-ve) (-ve) (-ve) (-ve)	(3.441) (5.008)	0.000 0.000 (3.214) (5.270)	(3.214) (5.270)	(5.270 (0.408
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current Trade Payables, Current Other Payables, Current Capital Payables, Current	£m £m £m £m £m	(-ve) (-ve) (-ve) (-ve)	(3.441) (5.008) (0.189)	0.000 0.000 (3.214) (5.270) (0.524)	(3.214) (5.270) (0.405)	(5.270 (0.408
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current Trade Payables, Current Other Payables, Current Capital Payables, Current Trade and Other Payables, Current, Total	£m £m £m £m £m	(-ve) (-ve) (-ve) (-ve) (-ve) (-ve)	(3.441) (5.008) (0.189) (8.638)	0.000 0.000 (3.214) (5.270) (0.524) (9.008)	(3.214) (5.270) (0.405) (8.889)	(5.270 (0.408 (8.892
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current Trade Payables, Current Other Payables, Current Capital Payables, Current Trade and Other Payables, Current, Total Other Financial Liabilities, Current Accruals, Current	£m ይጠ ይጠ ይጠ ይጠ ይጠ	(-ve) (-ve) (-ve) (-ve) (-ve) (-ve)	(3.441) (5.008) (0.189)	0.000 0.000 (3.214) (5.270) (0.524) (9.008) (4.456)	(3.214) (5.270) (0.405)	(5.270 (0.408 (8.892
Deferred Grant Income, Current Provisions, Current Post-Employment Benefit Obligation, Current Current Tax Payables Trade and Other Payables, Current Trade Payables, Current Other Payables, Current Capital Payables, Current Trade and Other Payables, Current, Total Other Financial Liabilities, Current	£m ይጠ ይጠ ይጠ ይጠ ይጠ	(-ve) (-ve) (-ve) (-ve) (-ve) (-ve)	(3.441) (5.008) (0.189) (8.638)	0.000 0.000 (3.214) (5.270) (0.524) (9.008)	(3.214) (5.270) (0.405) (8.889)	

			Actual at 31-Mar-13	Plan for 31-Mar-14	Plan for 31-Mar-15	Plan for 31-Mar-16
PDC dividend payable, Current	units	sense	31-Mar-13	0.000	31-War-15	31-Mar-16
Derivatives and embedded derivatives liabilities, current	£m £m	(-ve)		0.000		
Interest payable on bridging loans, current	£m	(-ve)		0.000		
Interest payable on non-commercial interest bearing borrowings, current	£m	(-ve)				
Interest payable on commercial interest bearing borrowings, current	£m	(-ve) (-ve)		0.000		
Other Accrued Financial Liabilities, Current				0.000		
	£m	(-ve)		0.000		
Other Financial Liabilities, Current	£m	(-ve)	(4 549)	0.000	(4.464)	(4.464)
Other Financial Liabilities, Current, Total	£m		(4.518)	(4.464)	(4.464)	(4.464)
Other Liabilities, Current	0	([]	0.000		
Donation income deferred to future periods	£m	(-ve)		0.000		
Liabilities in disposal groups classified as held for sale	£m	(-ve)		0.000		
Other Accrued Liabilities, Current	£m	(-ve)		0.000		
Other Liabilities, Current	£m	(-ve)		0.000	0.000	0.000
Other Liabilities, Current, Total Liabilities, Current, Total	£m £m		0.000 (17.205)	0.000 (14.893)	0.000 (14.779)	0.000 (14.788)
NET CURRENT ASSETS (LIABILITIES)	£m		10.776	11.088	11.802	12.353
Liabilities, Non-Current						
Interest-Bearing Borrowings, Non-Current						
Loans, Non-Current, non-commercial (DH, FTFF, NLF, etc)	£m	(-ve)	[0.000		[
Loans, Non-Current, commercial	£m	(-ve)		0.000		
		(-ve)	0.000		0.000	0.000
Interest-Bearing Borrowings, Non-Current, Total	£m	(0.000	0.000	0.000	0.000
Non-Interest-Bearing Borrowings, Non-Current	£m	(-ve)		0.000		
Deferred Income, Non-Current	£m	(-ve)		0.000		
Deferred Grant Income, Non-Current	£m	(-ve)		0.000		
Provisions, Non-Current	£m	(-ve)	(0.611)	(0.610)	(0.607)	(0.605)
Post-Employment Benefit Obligation, Non-Current	£m	(-ve)		0.000		
Deferred Tax liabilities	£m	(-ve)	L	0.000		
Trade and Other Payables, Non-Current				·		r
Trade Creditors, Non-Current	£m	(-ve)		0.000		
Other Creditors, Non-Current	£m	(-ve)		0.000		
Trade and Other Payables, Non-Current, Total	£m		0.000	0.000	0.000	0.000
Other Financial Liabilities, Non-Current						
Finance Leases, Non-current	£m	(-ve)	(0.013)	(0.013)	(0.013)	(0.013)
PFI leases, Non-Current	£m	(-ve)		0.000		
Derivatives and embedded derivatives liabilities, non-current	£m	(-ve)		0.000		
Other Financial Liabilities, Non-Current	£m	(-ve)		0.000		
Other Financial Liabilities, Non-Current, Total	£m		(0.013)	(0.013)	(0.013)	(0.013)
Other Liabilities, Non-Current						
Donated Assets deferred Income, Non-Current	£m	(-ve)		0.000		
Other Liabilities, Non-Current	£m	(-ve)		0.000		
Other Liabilities, Non-Current, Total	£m	(-)	0.000	0.000	0.000	0.000
Liabilities, Non-Current, Total	£m		(0.624)	(0.623)	(0.620)	(0.618)
TOTAL ASSETS EMPLOYED	£m		99.591	100.250	112.750	113.250
Taxpayers' and Others' Equity						
Non Controlling interest (was Minority Interest)	fm	(+)(0)		0.000		, ,
Taxpayers Equity	£m	(+ve)	L	0.000		L
Public dividend capital	£m	(+ve)	42.473	42.473	54.473	54.473
Retained Earnings (Accumulated Losses)	£m	(+ve)	19.608	21.882	24.043	25.945
Charitable Funds	£m	(+ve)		0.000		
Other Reserves		. ,		·		·····
Pensions Reserve	£m	(+ve)		0.000		
Revaluation Reserve	£m		37.510	35.895	34.234	32 832
Available for Sale Reserve	£m	(+ve)	07.010	0.000	07.2.04	32.832
		(+ve)				
Merger Reserve	£m	(+ve)		0.000		
Miscellaneous Other Reserves	£m	(+ve)		0.000		L
Other Reserves, Total TAXPAYERS EQUITY, TOTAL	£m £m		37.510 99.591	35.895 100.250	34.234 112.750	32.832 113.250
TOTAL ASSETS EMPLOYED	£m		99.591	100.250	112.750	113.250
Memorandum lines						
Working Capital Facility				,,		
Committed Working capital facility in place Figures for PBL calculation	£m	(+ve)	7.000	7.000	7.000	7.000
Planned Borrowings for PBL	£m	(+ve)	0.021	0.021	0.021	0.021
Figures for NRAF calculation	2.111	()	0.021	0.021	0.021	0.021
Taxpayers' equity			99.591	100.250	112.750	113.250
Leases			0.021	0.021	0.021	0.021
Borrowings			0.000	0.000	0.000	0.000
Finanacing (for FRR calculation)			99.612	100.271	112.771	113.271
Figures for Liquidity calculation Cash for liquidity purposes			15.518	15.791	16.852	17.528
			10.010	13.731	10.032	11.520

Planned Statement of Position for SOUTHTYNESIDE

South Tyneside NHS Foundation Trust

Surplus/(deficit) after tax

Tax expense

Planned Cash Flow Statement for SOUTHTYNESIDE

non-cash flows in operating surplus/(deficit)

Other operating non-cash movements

Gain/(loss) on disposal of intangible assets

Share of profit/(loss) loss from investments

Non-cash flows in operating surplus/(deficit), Total

Depreciation and amortisation, total Impairment losses/(reversals)

Share of profit/(loss) from equity accounted investments net of cash distributions receive

Donations & Grants received of PPE & intangible assets (not cash)

Other increases/(decreases) to reconcile to profit/(loss) from operations

Unrealised (gains)/losses on foreign currency exchange

Gain/(loss) on disposal of property plant and equipment

Operating Cash flows before movements in working capital

Finance income/charges

PDC dividend expense

					Enc 3
		Actual for	Plan for	Plan for	Plan for
5	sense	Year ending 31-Mar-13	Year ending 31-Mar-14	Year ending 31-Mar-15	Year ending 31-Mar-16
		(2.641)	0.659	0.501	0.499
	(+ve)		0.000	0.000	0.000
	(+ve)	(0.049)	(0.060)	(0.060)	(0.060)
	(+ve)		0.000		
	(+ve)		0.000		
	(+ve)	0.030	(0.027)	(0.025)	(0.024)
	(+ve)	4.887	4.953	4.953	4.953
	(+ve)	1.205	0.000	0.000	0.000
	(+ve)		0.000		
	(+ve)	0.032	0.000		
	(+ve)	0.003	0.000		
	(+ve)		0.000		
	(+ve)	2.797	2.706	2.706	2.706
	(+/-ve)		0.000		
		8.905	7.572	7.574	7.575

8.231

6.264

units

£m

£m

£m

£m

£m

£m

£m £m

£m

£m

£m

£m

£m

£m

7.574 7.575 8.075 8.074

Increase/(Decrease) in working capital						
(Increase)/decrease in inventories	£m	(increase -ve)	(0.160)	0.203		
(Increase)/decrease in tax receivable	£m	(increase -ve)		0.000		
(Increase)/decrease in NHS Trade Receivables	£m	(increase -ve)	1.835	(0.625)		
(Increase)/decrease in Non NHS Trade Receivables	£m	(increase -ve)	0.633	(0.069)		
(Increase)/decrease in other related party receivables	£m	(increase -ve)	(0.127)	(0.723)		
(Increase)/decrease in other receivables	£m	(increase -ve)	0.275	(0.038)		
(Increase)/decrease in accrued income	£m	(increase -ve)	0.070	(0.031)		
(Increase)/decrease in other financial assets	£m	(increase -ve)	0.070	0.000		
(Increase)/decrease in prepayments	£m	(increase -ve)	(0.176)	0.000		
(Increase)/decrease in Other assets (non chartable assets)	£m	(increase -ve)	0.036	(0.242)	0.347	0.125
Increase/(decrease) in Deferred Income (excl. Govt Grants.)	£m	(increase +ve)	0.142	0.001	0.047	0.120
Increase/(decrease) in Deferred Income (Govt. Grants)	£m	(increase +ve) (increase +ve)	0.142	0.000		
Increase/(decrease) in Current provisions	£m	(increase +ve) (increase +ve)	1.875	(2.630)	0.003	0.004
Increase/(decrease) in Trade Creditors	£m	(increase +ve) (increase +ve)	(0.821)	}	0.003	0.004
				(0.227)		
Increase/(decrease) in Other Creditors	£m	(increase +ve)	0.002	0.262		
Increase/(decrease) in accruals Increase/(decrease) in other Financial liabilities	£m £m	(increase +ve)	0.425	(0.054)		
Increase/(decrease) in Other liabilities (non charitable assets)		(increase +ve)	0.002	0.000		
Increase/(Decrease) in Other Habilities (non charitable assets)	£m £m	(increase +ve)	4.011	0.000 (4.173)	0.350	0.129
Increase/(Decrease) in Non-current Provisions	2111		4.011	0.000	0.330	0.123
Net cash inflow/(outflow) from operating activities	£m		10.275	4.058	8.424	8.204
Net cash innow/(outlow) nom operating activities	ZIII		10.275	4.038	0.424	0.204
Net cash inflow/(outflow() from investing activities			(
Property - new land, buildings or dwellings	£m	(-ve)	(1.576)	0.000	(12.000)	0.000
Property - maintenance expenditure Plant and equipment - Information Technology	£m £m	(-ve) (-ve)	(0.541) (0.614)	(0.813) (1.256)	(0.926) (1.135)	(2.650) (1.070)
Plant and equipment - Other	£m	(-ve)				
Property, plant and equipment - other expenditure	£m	(-ve) (-ve)	(1.850)	(1.751) (0.243)	(2.039) 0.000	(1.130) 0.000
Proceeds on disposal of property, plant and equipment	£m	(-ve) (+ve)	0.009	0.727	0.125	0.000
	£m		0.009	·		
Purchase of investment property	£m	(-ve)		0.000	0.000	0.000
Proceeds on disposal of investment property		(+ve)	(0.040)	0.000		0.000
Purchase of intangible assets	£m	(-ve)	(0.040)	0.000	0.000	0.000
Proceeds on disposal of intangible assets	£m	(+ve)	(4.040)	0.000	0.000	0.000
Expenditure on capitalised development Increase/(decrease) in Capital Creditors	£m £m	(-ve)	(1.910)	(1.960) 0.335	(0.761) (0.119)	(0.050) 0.003
Net cash inflow/(outflow() from investing activities, Total	£m	(-ve)	(7.471)	(4.961)	(16.855)	(4.897)
Net cash inflow/(outflow) before financing	£m		2.804	(0.903)	(8.431)	3.307
Net cash inflow/(outflow) from financing activities	0	()	0.007	0.000	40.000	
Public Dividend Capital received	£m	(-ve)	0.267	0.000	12.000	
Public Dividend Capital repaid	£m	(-ve)	(0.770)	0.000	(0.700)	(0.700)
PDC Dividends paid Interest element of finance lease rental payments - other	£m £m	(-ve)	(2.776)	(2.689)	(2.706)	(2.706)
		(-ve)	(0.009)	0.000		
Interest element of finance lease rental payments - On-balance sheet PFI	£m	(-ve)	(0.005)	0.000		
Capital element of finance lease rental payments - other	£m	(-ve)	(0.005)	0.000		
Capital element of finance lease rental payments - On-balance sheet PFI	£m	(-ve)	0.001	0.000	0.001	0.001
Interest received on cash and cash equivalents	£m	(+ve)	0.081	0.084	0.084	0.084
Movement in Other grants/Capital received	£m	(-ve)		0.000		
(Increase)/decrease in non-current receivables	£m	(-/+ve)	(0.005)	0.000		
Increase/(decrease) in non-current payables	£m	(+/-ve)		0.000		
Other cash flows from financing activities Net cash inflow/(outflow) from financing activities, Total	£m £m	(+/-ve)	(2.447)	0.000 (2.605)	9.378	(2.622)
Net increase/(decrease) in cash	£m		0.357	(3.508)	0.947	0.685
Opening cash	£m		19.914	20.271	16.763	17.710
Effect of exchange rates	£m	(+/-ve)		0.000		
Closing cash	£m		20.271	16.763	17.710	18.395
oroging cuon	LIII		20.271	10./03	17.710	10.395

Enc 3

South Tyneside NHS Foundation Trust Continuity of Service Shadow Risk Ratings (pilot indicators for 2013/14)

		Historic Year to 31-Mar-13	Plan for Year to 30-Jun-13	Plan for Year to 30-Sep-13	Plan for Year to 31-Dec-13	Plan for Year to 31-Mar-14	Plan for Year to 31-Mar-15	Plan for Year to 31-Mar-16
Debt Service Cover								
PDC dividend expense	from SoCI	(2.797)	(0.677)	(1.353)	(2.030)	(2.706)	(2.706)	(2.706)
Interest Expense on Overdrafts and Working Capital Facilities	from SoCI	-	-	-	-	-	-	-
Interest Expense on Bridging loans	from SoCI	-	-	-	-	-	-	-
Interest Expense on Non-commercial borrowings	from SoCI	-	-	-	-	-	-	-
Interest Expense on Commercial borrowings	from SoCI	-	-	-	-	-	-	-
Interest Expense on Finance leases (non-PFI)	from SoCI	(0.009)	-	-	-	-	-	-
Interest Expense on PFI leases & liabilities	from SoCI	-	-	-	-	-	-	-
Other Finance Costs	from SoCl	(0.024)	(0.005)	(0.011)	(0.016)	(0.022)	(0.022)	(0.022)
Non-Operating PFI costs (eg contingent rent)	from SoCI	-	-	-	-	-	-	-
Public Dividend Capital repaid	from SoCF	-	-	-	-	-	-	-
Repayment of bridging loans	from SoCF	-	-	-	-	-	-	-
Repayment of non-commercial loans	from SoCF	-	-	-	-	-	-	-
Repayment of commercial loans	from SoCF	-	-	-	-	-	-	-
Capital element of finance lease rental payments - On-balance s	het from SoCF	-	-	-	-	-	-	-
Capital element of finance lease rental payments - other	from SoCF	(0.005)	-	-	-	-	-	-
		-2.835	-0.682	-1.364	-2.046	-2.728	-2.728	-2.728
Revenue available for Debt Service Debt Service		8.651 -2.835	1.034 -0.682	3.692 -1.364	5.535 -2.046	8.340 -2.728	8.182 -2.728	8.180 -2.728
Debt Service Cover metric		3.05x	1.52x	2.71x	2.71x	3.06x	3.00x	3.00x
Debt Service Cover rating		4	2	4	4	4	4	4
Liquidity								
Cash for CoS liquidity purposes Operating Expenses within EBITDA, Total	from SoFP from SoCl	8.518 -208.310	7.434	7.532 -100.932	7.843 -151.480	8.791 -201.141	9.852 -198.547	10.528 -196.439
Liquidity metric		14.7	13.1	13.4	14.0	15.7	17.9	19.3
Liquidity rating		4	4	4	4	4	4	4
Continuity of Service Risk Rating		4	3	4	4	4	4	4

key to s	scoring		
Debt Serv	ice Cover	50%	
4	3	2	1
2.5	1.75	1.25	<1.25

key to scoring

Liquidity		50%	
4	3	2	1
-2	-7	-12	<-12

South Tyneside NHS Foundation Trust High level summary of financial plan of South Tyneside

fmNameNameNameNameNameOrdering Neuron GBIDA(16.5)(20.2)(20.6)(20.5)Dependent order GBIDA(16.7)(16.7)(16.7)(16.7)(16.7)Object(16.7)(16.7)(16.7)(16.7)(16.7)(16.7)BBIDA1.2.21.11.11.11.11.1Dependent order de montation(10.7)0.00.00.00.0BBIDA(10.7)0.00.00.00.00.0Dependent order de montation(10.7)0.10.10.10.1Nettories (Montant)0.10.10.10.10.10.1POC de forder de montation1.00.10.10.10.10.1POC de forder de montation1.00.10.10.10.10.1POC de forder de montation1.00.10.10.10.10.1POC de forder de montation1.00.10.10.10.10.1POC de forder de montation1.00.10.10.10.10.10.1POC de forder de montation1.00.10.10.10.10.10.10.1POC de forder de montation1.01.00.10.10.10.10.10.10.1POC de forder de montation1.01.01.01.00.10.10.10.10.1POC de forder de montation1.01.0	Figure stat Community	2012/13	2013/14	2014/15	2015/16
Space is pressure is termsPais </th <th>Financial Summary £m</th> <th></th> <th></th> <th></th> <th></th>	Financial Summary £m				
Enclose(17.7)(18.2)(17.3)(17.	Operating Revenue for EBITDA	216.5			
One on the interval inter		(157.7)	(149.2)	(147.3)	(145.6)
diff M proposed structuredif proposed structuredif proposed structuredif 		(5.8)	(5.7)		
Partial production of monotoning into (monotoning i					
import (pain (house (
Base of the server of					
Operating Support 12 13 11 11 With reading the second sec					
Alt lensities Work depresentations were berefined were and and an alternation of the section of the sec					
Disk Control Control <thcontrol< th=""> <thcontrol< th=""> <thcont< td=""><td></td><td></td><td></td><td></td><td></td></thcont<></thcontrol<></thcontrol<>					
Bit Shift (Motin) DB BT BS BT					
Second					
Chiral (Picing) N 2 7% 5 7%		(2.0)	0.7	0.0	0.5
Phy Chai Si My Const. N. 2 0% 4 38 3 8% 3 8% In Subjas / Constrained and strained strained and strained and strained strained and stra	EBITDA % Income	% 3.8%	3.9%	3.9%	4.0%
Nome of which which which we have a strain of which we have strain of which we have a strain of which we have a strain of whi	CIP% of Op.Exp. less PFI Exp.	% 4.7%	5.9%	5.5%	5.2%
Charan mutic cutic 40 42 14 0 1 Carlow form meeting suffice 10 10 10 10 Carlow form meeting suffice 10 10 10 10 10 Carlow form meeting suffice 10	Pay CIPs as % Pay Costs	% 2.0%	4.3%	3.8%	3.6%
Charan mutic cutic 40 42 14 0 1 Carlow form meeting suffice 10 10 10 10 Carlow form meeting suffice 10 10 10 10 10 Carlow form meeting suffice 10	Net Surplus / (Deficit)	(2.6)	0.7	0.5	0.5
Cathler from sparsters 40.3 41 44 42 Cathler from sparsters 7.0 0.0 0.0 0.0 0.0 Cathler for sparsters 7.0 0.0 0.0 0.0 0.0 0.0 Cathler for sparsters 7.0 0.0					
Canobia CS CS <t< td=""><td></td><td></td><td>7.6</td><td>7.6</td><td>7.6</td></t<>			7.6	7.6	7.6
Cathle whole functing interest lice and interest lice and int					
Call Colo Colo Colo Colo Colo Cash at consequences is parked 23.3 16.8 17.7 16.4 Cash at consequences is parked at	Cashflow from investing activities				
Att Increase licenses Add ISD Agd ISD Agd ISD Agd ISD					
Act and call 23.3 19.8 17.7 19.4 Cell and Cell sequences is a product set of the construct revenue 20.21/13 20.11/14 20.64/15 20.11/14 Construct revenue 0.9 0.8.4 0.2.5 0.11 Construct revenue 0.9 0.8.4 0.2.5 0.11 Construct revenue 0.9 0.8.4 0.2.5 0.1.4 Actor 0.9 0.8.4 0.2.5 0.1.4 Actor 0.9 0.8.4 0.2.5 0.1.4 Actor 0.9 0.4 0.0.5 0.0.4 0.0.5 Actor 0.9 0.0.4 0.0.5 0.0.6 0.0.6 0.0.6 Actor 0.0.5 0.0.5 0.0.6					
Cash and cash explorations starting summary 23 16.8 17.7 19.4 Commany Assume framework 23.0					
Detailed Plancial Summary 201011 20104 201014 201041 Pail Pail Co Coll Avoine contract reveal 9.2 8.3 8.2 8.1 Co Coll Avoine contract reveal 9.9 9.4 8.2 8.1 Co Coll Avoine contract reveal 9.7 9.3 9.1 9.1 Acted 9.7 9.3 9.1 9.1 9.1 Acted 9.7 9.3 9.1 9.1 9.1 Acted reveal 9.5 9.5 9.4 4.1 4.3 Acted reveal 9.5 9.4 4.1 4.3 9.3 Acted reveal 0.0 0.0 0.1 0.1 0.1 Coll Avoine contract reveal 0.0 0.0 0.0 0.1 0.1 Coll Avoine contract reveal 0.0 0.0 0.0 0.0 0.0 Coll Avoine contract reveal 0.0 0.0 0.0 0.0 0.0 Coll Avoine contract reveal 0.0 0.0 0.0 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
fm Actain Pan Pan Pan Pan Control & Julinat Contract versus 2 2 2 2 2 1 Control & Julinat Contract versus 90 0.3 0.2 0.1 0 Actar 15.5 13.7 13.5 13.4 0.0 0.0 A Note Schwins mean 25.5 5.6 0.4 0.0 0.0 0.0 A control for wersus 25.5 5.6 0.0 0.0 0.0 0.0 Control for wersus 0.0					
Construitive 1 1 1 Co Cot R Avenue 89 8.4 82.5 81.8 Cot R Avenue 89 8.4 82.5 81.8 Actar 35 33.5 33.4 82.5 81.8 Ave Decision revens 35.7 33.3 31.0 30.6 10.1 A Construit revens 35.5 55.4 43.1 33.3 30.6 10.1	Detailed Financial Summary £m				
C block cutrate revenue 96.9 83.4 82.5 81.6 Acate 13.5 13.5 13.5 13.4 A construction revenue 13.5 13.5 13.5 13.5 A construction revenue 25.5 55.4 4.9 4.9 A construction revenue 25.5 55.4 3.4 3.0 A construction revenue 26.6 20.0 0.0 0.0 C construction revenue 27.6 20.0 0.0 0.0 C construction revenue 27.6 20.0 0.00 0.0 C construction revenue 27.6 20.0 0.00 0.0 C construction revenue 27.6 20.0 1.0 0.0 C construction revenue 27.6 20.0 1.0 0.0 C construction revenue 1.0 27.6 1.0 1.0 0.0 C construction revenue 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Community				
Acts Second					
A.B. Beckelse revenue 13.6 13.7 13.5 13.4 A. Non-Seck revenue 13.6 13.7 13.5 13.4 A. Non-Seck revenue 13.6 13.7 13.5 13.4 A. Non-Seck revenue 13.6 13.6 13.6 13.7 13.5 13.4 A. Der revenue 13.6 13.7 13.6 13.6 13.7 13.5 13.4 Private prevenue 13.6 13.4 10 0.0 <td></td> <td>96.9</td> <td>83.4</td> <td>82.5</td> <td>81.6</td>		96.9	83.4	82.5	81.6
A. No-Edecine revue 35.7 31.3 31.0 30.6 A. Double revue 35.7 31.3 10.0 30.6 A. Double revue 28.5 30.4 43.1 33.3 Practs plater revue 28.5 30.4 43.1 33.3 Practs plater revue 0.0 0.0 0.1 0.1 Constant double assets 0.0 0.0 0.0 0.1 Tobe conting revenues 20.6 0.0 0.0 0.0 Constant double assets 0.0 0.0 0.0 0.0 Constant exerces 0.0 0.0					
A. Obdativit revnue 133 10.4 10.3 10.1 A. A.K. revnue 15.6 5.0 4.9 1.0 Protes guident revnue 0.0 0.0 0.0 0.0 Carts and durations in can 0.0 0.0 0.0 0.0 Carts and durations in can 13.4 2.19 2.21 2.24 Carts and durations in can 13.4 2.19 2.21 2.24 Carts and durations in can 13.6 2.00 2.00 0.0 0.0 Total coerting revenues 216.9 286.4 286.4 286.4 286.4 Endpore Exercise (15.7) (14.5) (14.5) (14.5) (14.5) Card coerting revenues (28.0) (28.1)	Ac Elective revenue	13.6	13.7		13.4
A.B.E revue 5.6 5.0 4.9 4.9 A.G.B.Trevue 2.8.5 3.5.4 3.1.1 3.3.3 Grate and Grators and A.G.B.Trevues 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 0.0 Control control revues for EBTOA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 </td <td>Ac Non-Elective revenue</td> <td>35.7</td> <td>31.3</td> <td>31.0</td> <td>30.6</td>	Ac Non-Elective revenue	35.7	31.3	31.0	30.6
Act off result 28.5 35.4 34.1 33.3 Prote plant results 0.0 0.0 0.1 0.1 Other coersing resources 1.3.4 2.1.9 2.2.4 2.2.4 Tack coersing resources 0.0 0.0 0.0 0.0 0.0 Tack coersing resources 2.0.6 2.0.6 2.0.6 2.0.6 2.0.6 Tack coersing resources 0.0 0.0 0.0 0.0 0.0 Tack coersing resources 1.0.6 0.0 0.0 0.0 0.0 Tack coersing resources 1.0.6 1.0.7 (145.2) (145.3) (15.1) Tack coersing resones (16.1) (14.3) (14.2) (16.1) (16.1) Tack coersing resones (20.1) (20.1) (20.1) (20.6) (20.6) Tack coersing resones (20.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) (21.1) </td <td>Ac Outpatient revenue</td> <td>13.9</td> <td>10.4</td> <td>10.3</td> <td>4.9</td>	Ac Outpatient revenue	13.9	10.4	10.3	4.9
Private prioriting number is a constrained of memory is more is a constrained of memory is more is a constrained of memory is more is a constrained of memory is constrained of memory is a constrained of memory is a	Ac other revenue	28.5	35.4	34.1	33.3
Other operating revenues 13.4 21.9 22.1 22.4 Carbot operating revenues 20.0 0.0 0.0 0.0 0.0 Carbot operating revenues 20.6 20.4 206.6 20.4 206.7 Carbot operating revenues 20.0 0.0 0.0 0.0 0.0 Enclopes Express (157.7) (140.2) (147.3) (145.6) (5.9) Other operating revenues within EBITOA 20.2 8.1 8.1 8.1 Depressing revenues within EBITOA 8.2 8.1 8.1 8.1 Depressing revenues within EBITOA 20.4 (20.4) (20.9) <td>Private patient revenue</td> <td>0.0</td> <td>0.0</td> <td>0.1</td> <td>0.1</td>	Private patient revenue	0.0	0.0	0.1	0.1
Total accessing revenue for BBTDA Crants and downloss of PPE and htampble assis 216.9 200.4 206.6 204.5 Carls and downloss of PPE and htampble assis 216.9 209.4 206.5 200.5 Carls and downloss of PPE and htampble assis 216.9 209.4 206.5 200.5 Drag separate Drag separate Supplies (inclical An orchical) (157.7) (146.2) (147.3) (145.5) Carls and downloss within EBTDA (58.9) (215.1) (145.5) (149.2) (147.1) Carls and contrains expenses within EBTDA (208.3) (201.1) (149.5) (169.1) Carls and contrains expenses (200.1) (200.1) (200.1) (200.1) Carls and contrains expenses (200.1) (200.1) (200.1) (200.1) Carls and contrains expenses (200.1) (200.1) (200.1) (200.1) (200.1) Carls and solar and anomination (200.1) (200.1) (200.1) (200.1) (200.1) (200.1) Carls and solar and anomination (200.1) (200.1) (200.1) (200.1) (200.1)					
Operation and products of PPE and inlanguble assets 0.0 0.0 0.0 Craid overating revenues 216.9 209.4 266.9 204.5 Enclayee Expenses Supples (clinical A non-clinical) (5.8) (5.7) (6.8) (5.8) Craid overating expenses (22.6) (21.6) (21.3) (20.5) Craid and another difference (22.8) (21.6) (21.3) (20.6) Craid and another difference (22.8) (20.1) (196.5) (5.6) Craid and another difference (22.3) (20.1) (20.6.5) (20.6.5) Craid another difference (22.3) (20.1) (20.6.5) (20.6.5) Craid another difference (2.3) (20.1) (20.6.5) (20.7) Craid another difference (2.5) (1.6) (1.8) (20.6.5) Craid another difference (2.5) (2.6) (2.7) (2.7) Craid another difference (2.5) (2.7) (2.7) (2.7) Craid another difference (2.5) (2.7) (2.7) (2.	Other operating revenues				
Total accenting revenue 216.9 206.4 206.6 204.5 Enployee Exenses (157.7) (142.7) (142.6) (145.6) Suppose (number accounting) (151.1) (145.6) (145.6) (145.6) Other expenses (206.5) (201.1) (196.5) (196.4) Cala operating revenses (206.5) (201.1) (196.6) (196.7) Cala operating sequenses within EUTDA 2.2 8.1 8.1 8.1 Derivation and anonisation important & Restructuring (200.0) (200.0) (200.0) (200.0) Cala operating sequenses within EUTDA (230.4) (11.6) (208.5) (200.5) Cala operating sequenses action association and anonisation importance in the sequenses (200.0) 0.0 0.0 0.0 Cala operating sequenses action association association and anonisation importance in the sequenses (200.0) (200.0) 0.0 0.0 Cala operating sequenses (200.0) 0.0 0.0 0.0 0.0 Cala operating sequenses (200.0) 0.0 0.0 0.0<	Total operating revenue for EBITDA				
Drugs separate Supplies (inclus) (5.9) (5.7) (6.8) (5.9) Supplies (inclus) (15.1) (14.5) (14.2) (14.1) Deparation on conserve with IEBTDA (20.8.3) (20.1) (19.6.6) (19.6.7) EBTDA (20.8.3) (20.1) (19.6.6) (19.6.7) (19.6.7) Deparation and monisation impairments & Restructuring (20.4) (21.6) (20.6.7) (20.7) Cala operating sequences (20.4) (21.6) (20.6.7) (20.7) (20.7) Cala operating sequences (20.4) (21.6) (20.6.7) (20.7) (20.7) (20.7) Calar (sets) most disposal Gain (sets	Total operating revenue				
Drugs separate Supplies (inclus) (5.9) (5.7) (6.8) (5.9) Supplies (inclus) (15.1) (14.5) (14.2) (14.1) Deparation on conserve with IEBTDA (20.8.3) (20.1) (19.6.6) (19.6.7) EBTDA (20.8.3) (20.1) (19.6.6) (19.6.7) (19.6.7) Deparation and monisation impairments & Restructuring (20.4) (21.6) (20.6.7) (20.7) Cala operating sequences (20.4) (21.6) (20.6.7) (20.7) (20.7) Cala operating sequences (20.4) (21.6) (20.6.7) (20.7) (20.7) (20.7) Calar (sets) most disposal Gain (sets					
Supplies (clinical 4 non-clinical) (15.1) (14.2) (14.2) (14.1) Chile sequenes (23.6) (21.6) (21.3) (20.6) Embore (23.6) (21.6) (21.3) (20.6) Embore (23.6) (21.6) (21.7) (21.6) Embore (23.9) (20.0) (20.0) (20.0) Cold operating expenses (22.0) (20.0) (20.0) (20.0) Gain (toss) for asset disposal (20.0) 0.0 0.0 0.0 Gain (toss) for asset disposal 0.0 0.0 0.0 0.0 Net interest 0.1 0.1 0.1 0.1 Taxation 0.0 0.0 0.0 0.0 PDC dividend (2.8) (2.7) (2.7) (2.7) Change in Current Resolutations (2.8) (2.7) (2.7) (2.7) Vident Resolutations 0.0 0.0 0.0 0.0 0.0 PDC dividend 0.2 0.2 0.0 0.0					
Other sequences (20) (310) (13.3) (20.9) Cotal operating sequences (26.3) (20.1) (18.5) (20.9) EBITDA 8.2 8.1 8.1 8.1 8.1 Dependence and envitation (4.9) (5.0) (5.0) (5.0) Operating Surplus (Defici) (22.04) (21.0) (206.5) (206.3) Operating Surplus (Defici) (3.5) (1.5) (1.6) (0.0) Gain (bes) on asset disposal (0.0) 0.0 0.0 0.0 Gain (bes) on asset disposal (0.0) 0.0 0.0 0.0 Taxition 0.0 0.0 0.0 0.0 0.0 Taxition 0.0 0.0 0.0 0.0 0.0 K Surplus (Defici) (2.9) 0.7 0.5 0.5 EBITDA 2.2 8.1 8.1 8.1 8.1 Change in Current Pacebales 0.8% 3.9% 3.9% 4.0% Change in Current Pacebales 0.5	Supplies (clinical & non-clinical)		(5.7)	(0.6)	
BetTOA Impairments & Restructuring impairments & Restructuring (2.3) 8.1 8.1 8.1 Deprectiation and anotisation impairments & Restructuring (2.3) (50) (50) (60) Total operating separes (2.0) (2.0) (2.0) (2.0) Operating separes (2.0) (2.0) (2.0) (2.0) Gain (loss) on asset dispoal Gain(loss) for transfer by absorbtion 0.0 0.0 0.0 0.0 Net interest 0.1 0.1 0.1 0.1 0.0 0.0 Define (loss) on asset dispoal Gain(loss) for transfer by absorbtion (2.8) (2.7) (2.7) (2.7) Other non-operating latens (2.8) 0.1 (0.0) (0.0) 0.0 Not prevenue 3.8% 3.9% 3.9% 4.0% EBITDA 8.1 8.1 8.1 Change in Curren Revenue 2.8 (1.9) 0.0 0.0 Change in Curren Revenue (3.9) 0.0 0.0 0.0 Change in Curren Revenue 2.8 (1.9) 0.1 0.0 <					
BetTOA Impairments & Restructuring impairments & Restructuring (2.3) 8.1 8.1 8.1 Deprectiation and anotisation impairments & Restructuring (2.3) (50) (50) (60) Total operating separes (2.0) (2.0) (2.0) (2.0) Operating separes (2.0) (2.0) (2.0) (2.0) Gain (loss) on asset dispoal Gain(loss) for transfer by absorbtion 0.0 0.0 0.0 0.0 Net interest 0.1 0.1 0.1 0.1 0.0 0.0 Define (loss) on asset dispoal Gain(loss) for transfer by absorbtion (2.8) (2.7) (2.7) (2.7) Other non-operating latens (2.8) 0.1 (0.0) (0.0) 0.0 Not prevenue 3.8% 3.9% 3.9% 4.0% EBITDA 8.1 8.1 8.1 Change in Curren Revenue 2.8 (1.9) 0.0 0.0 Change in Curren Revenue (3.9) 0.0 0.0 0.0 Change in Curren Revenue 2.8 (1.9) 0.1 0.0 <		(208.3)	(201.1)	(198.5)	(196.4)
Depreciation and amonifaction (4.5) (5.0) (5.0) (5.0) Impairments & Restructuring (2.20.4) (2.11.0) (2.06.5) (2.06.3) Operating expenses (2.20.4) (2.11.0) (2.06.5) (2.00.5) Gain (loss) for asset dispoal (0.0) 0.0 0.0 0.0 Gain (loss) for asset dispoal (0.0) 0.0 0.0 0.0 Net interest 0.0 0.0 0.0 0.0 0.0 Viet Amonifaction (2.8) (2.7) (2.7) (2.7) (2.7) Other non-operating terms (2.8) 0.1 (0.0) 0.0 0.0 Other non-operating terms (2.8) 0.7 0.5 0.5 EBTDA 0.0 0.0 0.0 0.0 0.0 Other non-operating terms (2.8) 0.0 0.0 0.0 Charge in Current Payables (2.8) 0.0 0.0 0.0 Other non-operating terms (2.8) 0.0 0.0 0.0 Charge in Current					
Impairments & Restructing (2.3) 0.0 0.0 Clad operating scrptuse (Policit) (2.3) (2.4) (21.0) (2.6) (2.3) Gain (loss) from transfer by absorbtion (0.0) 0.0 0.0 0.0 Gain (loss) from transfer by absorbtion 0.0 0.0 0.0 0.0 Net interest 0.0 0.0 0.0 0.0 0.0 PDC dividend 0.0 0.0 0.0 0.0 0.0 Other non-coerdina tems 0.0 0.0 0.0 0.0 0.0 Net surplus / Deficit) (2.6) 0.7 0.5 0.5 0.5 EBITDA 8.2 8.1 8.1 8.1 8.1 Change in Current Receivables 2.6 (1.5) 0.0 0.0 Other on-cash tems (0.6) 0.0 0.0 0.0 Other on-cash tems (1.9) 0.1 (0.0) 0.0 Other on-cash tems (1.9) 0.1 0.0 0.0 Change in Current Repabl					
Total operating expenses (22.04) (21.0) (20.65) (20.63) Operating Surplus (belicit) (3.5) (1.6) (1.6) (1.6) (1.6) Gain (boss) on asset disposal (0.0) 0.0 0.0 0.0 0.0 Gain (boss) on asset disposal 0.0 0.0 0.0 0.0 0.0 Gain (boss) on asset disposal 0.1 0.1 0.1 0.1 0.1 Tazion 0.0 0.0 0.0 0.0 0.0 0.0 PDC divided (2.8) 0.7 0.5 0.5 EBITDA % of Op. revenue 3.8% 3.9% 3.9% 4.0% Change in Current Receivables 2.6 1.1 8.1 8.1 Change in Current Receivables 1.9 0.1 0.0 0.0 Change in Current Receivables 1.9 0.1 0.0 0.1 Change in Current Receivables 1.9 0.1 0.0 0.1 Change in Current Receivables 1.9 0.1 0.0 0.1	Impairments & Restructuring	(4.9)			
Operating Surplus (Deficit) (1.8) (1.8) (1.8) (1.8) Gain (Loss) on asset disposal (Loss) on as	Total operating expenses	(220.4)			
Gain (loss) on asset disposal (0,0) 0.0 0.0 Gain (loss) for transfer by absorbtion 0.0 0.0 0.0 Net interest 0.1 0.1 0.1 0.1 Tacation 0.0 0.0 0.0 0.0 POC dividend (2.8) (2.7) (2.7) (2.7) Other non-versitin items 0.6 0.6 0.6 Net Surplus / (Deficit) 2.6) 0.7 0.5 0.5 EBITDA Sd Op, revenue 3.8% 3.9% 3.9% 4.0% Change in Current Receivables 2.6 (1.5) 0.0 0.0 Change in Current Receivables 2.6 (1.5) 0.0 0.0 Other changes in WC 2.2 (2.8) 0.3 0.1 Other changes in WC 0.0 0.7 0.1 0.0 Cabified from coceratin activities 0.0 0.7 0.1 0.0 Cabified from coceratin activities 0.0 0.7 0.1 0.0 Cabified cocoref financ					
Gain/(loss) from transfer by absorbtion 0.0 0.0 0.0 0.0 Net interest 0.1 0.1 0.1 0.1 Taxation 0.0 0.0 0.0 0.0 PDC dividend (2.8) (2.7) (2.7) Other non-operating terms 0.8 0.1 0.0 0.0 Re Surplis (Deficit) (2.6) 0.7 0.5 0.5 EBITDA % of On revenue 3.8% 3.9% 3.9% 4.0% EBITDA for chances in WC 2.6 (1.5) 0.0 0.0 Other chances in WC 2.8 (2.8) 0.3 0.0 Other chances in WC 2.8 (0.3) 0.0 0.0 Change in Current Reveables (1.9) 0.1 0.0 0.0 Change in Current Reveables (2.8) 0.3 0.0 0.0 Other concasi herms (1.9) 0.1 0.0 0.0 0.0 0.0 Change in Current Reveables (3.7) (4.9) 0.2 0.0 <td< td=""><td></td><td></td><td></td><td></td><td>(1.8)</td></td<>					(1.8)
Net interest 0.1 0.1 0.1 0.1 0.1 Taxation 0.0 0.0 0.0 0.0 0.0 PDC dividend (2.8) (2.7) (2.7) (2.7) (2.7) Other non-ogenatina lens (2.6) 0.7 0.5 0.5 EBITDA % of Op. revenue 3.8% 3.9% 3.9% 4.0% EBITDA % of Op. revenue 3.8% 3.9% 3.9% 4.0% EBITDA % of Op. revenue 3.8% 3.9% 3.9% 4.0% Change in Current Receivables 2.6 (1.5) 0.0 0.0 Change in Current Receivables (2.8) 0.3 0.1 0.0 Change in Current Receivables (1.8) 0.1 (0.0) 0.0 Cashforw from operating actinity is (1.9) 0.1 (0.0) 0.0 Cashforw form conceads (0.0 0.7 (1.1) 0.0 Cashforw form conceads (0.0) 0.0 0.0 0.0 Cashforw form conceads (0.0)					
Taxion 0.0 0.0 0.0 0.0 0.0 PDC dividend Other non-operating lems (2.8) (2.7) (2.7) (2.7) Re Surplis (Dificit) (2.6) 0.7 0.6 0.5 EBITDA % of On revenue 3.8% 3.9% 3.9% 4.0% EBITDA (Chrange in Current Receivables Change in Current Receivables 2.6 (1.5) 0.0 0.0 Change in Current Repaibles (2.6) 0.2 0.0 0.0 Other non-operating lexivities (2.6) 0.0 0.0 0.0 Other non-operating lexivities (2.6) 0.0 0.0 0.0 Other non-operating lexivities (2.6) 0.0 0.0 0.0 Change in Current Receivables (2.6) 0.0 0.0 0.0 Other non-operating lexivities (3.8) 0.0 0.0 0.0 Cash on operating cash flows (2.7) (2.8) 0.0 0.0 Cash on operating cash flows (3.7) (2.0) (1.1) 0.0 Cash o	Gain (loss) on asset disposal	(0.0) 0.0	0.0 0.0	0.0 0.0	0.0 0.0
Other non-operating lemms (0.6) 0.1 (0.0) (0.0) Ret Surplus (Oefficity) 2.6) 0.7 0.5 0.5 EBITDA % of Os revenue 3.8% 3.9% 3.9% 4.0% EBITDA (Sorterent Papelses) 2.6 6.1 8.1 8.1 Change in Current Papelses 2.6 (1.5) 0.0 0.0 Other non-operating lexibilies 2.2 (2.8) 0.3 0.1 Other non-operating lexibilies (1.9) 0.1 (0.0) 0.0 Other non-operating lexibilies (1.9) 0.1 (0.0) 0.0 Other non-operating lexibilies (1.9) 0.1 (0.0) (0.0) Change in Current Papelses (1.9) 0.1 (0.0) (0.0) Other non-operating lexibilies (1.9) 0.1 (0.0) (0.0) Caplate sequentilies (securit) (1.9) (2.0) (1.1) (1.0) Caplate sequentilies (securit) (2.8) (2.7) (2.7) (2.7) Caplate sequentilies (securit) <td>Gain (loss) on asset disposal Gain/(loss) from transfer by absorbtion</td> <td>(0.0) 0.0 0.1</td> <td>0.0 0.0 0.1</td> <td>0.0 0.0 0.1</td> <td>0.0 0.0 0.1</td>	Gain (loss) on asset disposal Gain/(loss) from transfer by absorbtion	(0.0) 0.0 0.1	0.0 0.0 0.1	0.0 0.0 0.1	0.0 0.0 0.1
Not Surplus / (Deficit) 0.7 0.5 0.5 EBITDA % of Op. revenue 3.8% 3.9% 3.9% 4.0% EBITDA % of Op. revenue 3.8% 3.9% 3.9% 4.0% EBITDA for Op. revenue 8.2 8.1 8.1 8.1 Change in Current Receivables 2.6 (1.5) 0.0 0.0 Change in Current Payables 0.08 0.0 0.0 0.0 Other changes in WC 2.2 (2.8) 0.3 0.1 Cashforw from coverating activities 10.3 4.1 8.4 8.2 Cashforw from coverating activities 10.3 4.1 8.4 8.2 Cashforw form coverating activities 0.0 0.7 0.1 0.0 Cashforw form contig cash flows (1.9) (2.0) (2.0) (1.1) Cashforw form coverating cash flows (2.0) (2.0) (1.1) (2.7) Cashforw form financing 2.8 (0.9) (8.4) 3.3 Net interest 0.0 0.0 0.0 </td <td>Gain (loss) on asset disposal Gain/(loss) from transfer by absorbtion Net interest Taxation</td> <td>(0.0) 0.0 0.1 0.0</td> <td>0.0 0.0 0.1 0.0</td> <td>0.0 0.0 0.1 0.0</td> <td>0.0 0.0 0.1 0.0</td>	Gain (loss) on asset disposal Gain/(loss) from transfer by absorbtion Net interest Taxation	(0.0) 0.0 0.1 0.0	0.0 0.0 0.1 0.0	0.0 0.0 0.1 0.0	0.0 0.0 0.1 0.0
EBITDA % of Op. revenue 3.8% 3.9% 3.9% 4.0% EBITDA Change in Current Receivables Change in Current Payables 2.8 1.1 8.1 8.1 Change in Current Payables 0.08 0.00 0.0 0.0 Other non-shiftens (1.5) 0.0 0.0 Other non-shiftens (1.5) 0.0 0.0 Cash of whom operating activities (1.9) 0.1 0.0 0.0 Cash of whom operating activities (1.9) 0.1 0.0 0.0 Cash of whom operating activities (1.9) 0.1 0.0 0.0 Cash of whom operating activities (1.9) (2.0) (2.0) 0.0 Cash of whom operating activities (1.9) (2.0) (2.0) 0.0 Cash of whom operating activities (0.0) 0.0 0.0 0.0 Cash of whom operating activities (2.8) (2.0) (2.0) (2.0) Cash of whom operating activities (0.0) 0.0 0.0 0.0 Cash of (0.0) 0.0	Gain (loss) on asset disposal Gain(loss) from transfer by absorbtion Net interest Taxation PDC dividend	(0.0) 0.0 0.1 0.0 (2.8)	0.0 0.0 0.1 0.0 (2.7)	0.0 0.0 0.1 0.0 (2.7)	0.0 0.0 0.1 0.0 (2.7)
Bit DA Change in Current Receivables 8.2 8.1 8.1 8.1 Change in Current Reveables 2.6 (1.5) 0.0 0.0 Other chances in WC 2.2 (2.8) 0.3 0.1 Other non-san Hems (1.9) 0.1 (0.0) (0.0) Cashidow from operating activities (1.9) 0.1 (0.0) (0.0) Cashidow from operating activities (1.9) (1.49) (3.8) (3.8) Cashidow forto financing (2.8) (2.0) (1.1) (1.1) Cashidow forto financing (2.8) (2.6) (2.1) (2.0) PDC dividencing (cashift) (2.8) (2.7) (2.7) (2.7) Movement in bans (2.8) (2.8) (2.7) (2.7) PDC dividencing cashiftows (0.0) (0.0) (0.0) (0.7) Movement in bans (0.0) (0.0) (0.0) (0.7) (0.1) PDC dividencing cashiftows (0.1) (0.1) (0.1) (0.1) Not cash inflow (outi	Gain (loss) on asset disposal Gain/(loss) from transfer by absorbtion Net interest Taxation PDC dividend Other non-operating items	(0.0) 0.0 0.1 0.0 (2.8) (0.8)	0.0 0.0 0.1 0.0 (2.7) 0.1	0.0 0.0 0.1 0.0 (2.7) (0.0)	0.0 0.0 0.1 0.0 (2.7) (0.0)
Change in Current Revolutions 2.6 (1.5) 0.0 0.0 Other on-carrent Payables (0.8) 0.0 0.0 0.0 Other on-cash literns (1.9) 0.1 (0.0) 0.0 Cashing on count of payables (1.9) 0.1 (0.0) (0.0) Cashing on count of payables (1.9) 0.1 (0.0) (0.0) Cashing on count of payables (1.9) 0.1 (0.0) (0.0) Cashing on count of payables (1.9) (2.0) (1.1) (1.0) <td>Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net interest Taxation PDC dividend Other non-overlaing items Net Surplus / (Deficit)</td> <td>(0.0) 0.0 0.1 (2.8) (0.8) (2.6)</td> <td>0.0 0.1 0.0 (2.7) 0.1 0.1</td> <td>0.0 0.1 0.1 (2.7) (0.0) 0.5</td> <td>0.0 0.1 0.0 (2.7) (0.0) 0.5</td>	Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net interest Taxation PDC dividend Other non-overlaing items Net Surplus / (Deficit)	(0.0) 0.0 0.1 (2.8) (0.8) (2.6)	0.0 0.1 0.0 (2.7) 0.1 0.1	0.0 0.1 0.1 (2.7) (0.0) 0.5	0.0 0.1 0.0 (2.7) (0.0) 0.5
Change in Current Payables (0.8) 0.0 0.0 0.0 Other change in WC 2.2 (2.8) 0.3 0.1 Other changes in WC (1.9) 0.1 (0.0) (0.0) Other changes in WC (1.9) 0.1 (0.0) (0.0) Cashflow from coreating activities (1.0) (1.4) 8.4 8.2 Cashflow from coreating activities (5.6) (3.7) (14.9) (3.8) Cashflow from coreating activities (0.0) 0.7 0.1 0.0 Cashflow from framcing 2.8 (0.9) (8.4) 3.3 Cashflow ford (faid) (2.8) (2.7) (2.7) (2.7) Movement in loans 0.0 0.0 0.0 0.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 0.0 Donations received in cash 0.1 0.1 0.1 0.1 0.1 Donations received in cash four (utiflow) 0.4 (5.5) 0.9 0.7 Cash a	Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net interest Taxation PDC dividend Other non-overlaing items Net Surplus / (Deficit)	(0.0) 0.0 0.1 (2.8) (0.8) (2.6)	0.0 0.1 0.0 (2.7) 0.1 0.1	0.0 0.1 0.1 (2.7) (0.0) 0.5	0.0 0.1 0.0 (2.7) (0.0) 0.5
Other chances in WC 22 (2h) 0.3 0.1 Other on-cash litems (19) 0.1 (00) (00) Cashidow from operating activities 10.3 4.1 8.4 8.2 Cashidow from operating activities 10.3 4.1 8.4 8.2 Cashidow from operating activities 6.56 (3.7) (14.9) (3.8) Asset sile proceeds 0.0 0.7 0.1 0.0 Asset sile proceeds 0.0 0.7 0.1 0.0 Other investing cash flows 0.20 (2.0) (1.1) 0.0 Cashidow before financing 2.8 (0.9) (8.4) 0.3 Net interest 0.0 0.0 0.0 0.0 PDC dividends (paid) (2.6) (2.7) (2.7) (2.7) Movement in bars 0.0 0.0 0.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 Donations received in cash 0.1 0.1 0.1 0.1	Gain (loss) or asset disposal Gain/(loss) from transfer by absorbtion Net interest Taxation PDC dividend Other non-operating items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA	(0.0) 0.0 0.1 0.0 (2.8) (0.6) (2.6) 3.8% 8.2	0.0 0.0 0.1 0.1 0.7 0.1 0.7 3.9% 8.1	0.0 0.0 0.0 0.0 0.0 0.0 0.5 3.9% 8.1	0.0 0.0 0.1 0.0 (2.7) (0.0) 0.5 4.0% 8.1
Other non-cash lens (1.9) 0.1 (0.0) (0.0) Cashflow from operating activities 10.3 4.1 8.4 8.2 Cashflow from operating activities 0.0 0.7 0.1 0.0 Asset sale roceeds 0.0 0.7 0.1 0.0 other investing cash flows (1.9) (2.0) (2.0) (1.1) Cashflow for functing 2.8 (0.0) 0.0 0.0 Cashflow for functing 2.8 (0.0) 0.0 0.0 Net interest 0.0 0.0 0.0 0.0 0.0 PDC dividents (rabid) (2.8) (2.7) (2.7) (2.7) Movement in loans 0.0 0.0 0.0 0.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 0.0 Donations received in cash 0.1 0.1 0.1 0.1 0.1 Net cash inflow (outflow) 0.4 (5.5) 0.9 0.7 Cash at V/E 20.3 <td>Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net Interest Taxation PDC dividend Other non-operating items Other non-operating items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables</td> <td>(0.0) 0.0 0.1 0.0 (2.8) (2.8) (2.6) 8.2 2.6</td> <td>0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 7 3.9% 8.1 (1.5)</td> <td>0.0 0.0 0.1 0.0 (2.7) (0.0) 0.5 3.9% 8.1 0.0</td> <td>0.0 0.0 0.1 0.0 (2.7) (0.0) 0.5 4.0% 8.1 0.0</td>	Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net Interest Taxation PDC dividend Other non-operating items Other non-operating items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables	(0.0) 0.0 0.1 0.0 (2.8) (2.8) (2.6) 8.2 2.6	0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 7 3.9% 8.1 (1.5)	0.0 0.0 0.1 0.0 (2.7) (0.0) 0.5 3.9% 8.1 0.0	0.0 0.0 0.1 0.0 (2.7) (0.0) 0.5 4.0% 8.1 0.0
Cashforw from operating activities 10.3 4.1 8.4 8.2 Cashial work from operating activities (10.3) (14.9) (3.8) Cashial work sale proceeds 0.0 0.7 0.1 0.0 Asset sale proceeds 0.0 0.7 0.1 0.0 Cashial work of the imensing cash flows (19) (2.0) (1.1) Cashial work of the imensing cash flows 2.8 (0.9) (8.4) 0.3 Net interest (0.0) 0.0 0.0 0.0 0.0 PDC dividents (radi) (2.8) (2.7) (2.7) (2.7) Movement in bars 0.0 0.0 0.0 0.0 Donators received in cash 0.0 0.0 0.0 0.0 Other financing cashflows 0.1 0.1 0.1 0.1 Net inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at Y/E 20.3 16.8 17.7 18.4	Gain (loss) on assed laposal Gain(loss) from transfer by absorbtion Net interest Taxation PDC dividend Other non-operatina items Ket Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Payables	(0.0) 0.0 0.1 0.0 (2.8) (0.8) (2.6) 3.8% 8.2 2.6 (0.6)	0.0 0.0 0.1 0.0 0.1 0.1 0.7 0.7 3.9% 8.1 (1.5) 0.0	00 01 00 (27) (00) 0.5 3.9% 8.1 0.0	0.0 0.0 0.1 0.0 (2.7) (0.0) 0.5 4.0% 8.1 0.0 0.0
Capital expenditure (acurals basis) (5.6) (3.7) (14.9) (3.8) Asset sale proceeds 0.0 0.7 0.1 0.0 other investing cash flows (1.9) (2.0) (2.1) (1.1) Cashflow Sorrogen financing 2.8 (0.9) (8.4) 3.3 Net interest (0.0) 0.0 0.0 0.0 PDC dividers (adid) (2.8) (2.7) (2.7) (2.7) Movement in loans 0.0 0.0 0.0 0.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 0.0 other financing cashflows 0.1 0.1 0.1 0.1 0.1 Not cash inflow (utiflow) 0.4 (3.5) 0.9 0.7 18.4	Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net Interest Taxation PDC dividend Other non-overling items Net Surplus / (Deficit) EBITDA % of Oo. revenue EBITDA Change in Current Receivables Change in Current Receivables Change in Current Receivables Change in Current Receivables Change in WC	(0.0) 0.0 0.1 0.0 (2.8) (2.8) (2.6) 3.8% 8.2 2.6 (0.6) 2.2	0.0 0.0 0.1 0.0 (2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8)	00 01 00 (27) (00) 0.5 3.9% 8.1 0.0 0.0 0.3	0.0 0.0 0.1 0.0 (2.7) (0.0) 0.5 4.0% 8.1 0.0 0.0 0.1
other investing cash flows (1.9) (2.0) (1.1) Cash flow before financing 2.8 (0.9) (8.4) 3.3 Net interest (0.0) 0.0 0.0 0.0 PDC dividers (aid) (2.8) (2.7) (2.7) (2.7) Movement in loans 0.0 0.0 0.0 0.0 Dendations received in cash 0.0 0.0 0.0 0.0 Other financing cashflows 0.1 0.1 0.1 0.1 Not cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at YE 20.3 16.8 17.7 18.4	Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net Interest Taxation PDC dividend Other non-coerating items Net Surplus / (Deficit) EBITDA % of Oo. revenue EBITDA Change in Current Receivables Change in Durent Receivabl	(0.0) 0.0 0.1 0.0 (2.8) (2.8) (2.6) 3.8% 8.2 2.6 (0.8) 2.2 (1.9) 10.3	0 0 0 0 0 1 0 0 0 27) 0 1 0 7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 4.1	00 00 01 00 (27) (00) 0.5 3.9% 8.1 0.0 0.0 0.3 (00) 8.4	00 00 01 00 (27) (00) 0.5 4.0% 8.1 0.0 0.0 0.1 (00) 8.2
Cashidow before financing 2.8 (0.9) (8.4) 3.3 Net interest (0.0) 0.0 0.0 0.0 PDC dividends (paid) (2.8) (2.7) (2.7) (2.7) Morement in loans 0.0 0.0 0.0 0.0 DPDC received/(repaid) 0.3 0.0 12.0 0.0 Donations received in cash 0.1 0.1 0.1 0.1 Net cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at YIE 20.3 16.8 17.7 18.4	Gain (loss) on assed laposal Gain(loss) from transfer by absorbtion Net interest Tazaion PDC dividend Other non-operating lems Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Other on-cash items Other changes in WC Other non-cash items Cashidow from operating activities Cashidow from operating activities Cashidow from operating activities	(0.0) 0.0 0.1 0.0 (2.8) (0.8) (2.6) 3.8% 8.2 2.6 (0.6) 2.2 (1.9) 10.3 (5.6)	0 0 0.0 0.1 0.0 (2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 4.1 (3.7)	00 01 00 (27) (00) 05 8.1 00 00 00 03 (00) 8.4 (14.9)	0.0 0.0 0.1 0.0 (2.7) (0.0) 0.0 4.0% 8.1 0.0 0.0 0.0 0.1 (0.0) 8.2 (3.8)
Net interest (0.0) 0.0 0.0 0.0 PDC dividents faild) (2.8) (2.7) (2.7) (2.7) Movement in loans 0.0 0.0 0.0 0.0 Donations received in eash 0.0 0.0 0.0 0.0 Donations received in eash 0.0 0.0 0.0 0.0 Not cash inflow (outflow) 0.1 0.1 0.1 0.1 Net cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash and Cash quivalents at Y/E 20.3 16.8 17.7 18.4	Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net Indrest Taxation PDC dividend Other non-coarding items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Cha	(0.0) 0.0 0.1 0.0 (2.8) (2.8) (2.8) 2.8% 8.2 2.6 (0.8) 2.2 (1.9) 10.3 (5.6) 0.0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 4.1 (3.7) 0.7	00 00 01 00 (27) (00) 0.5 3.9% 8.1 0.0 0.0 0.3 (0.0) 8.4 (14.9) 0.1	0 0 0 0 0 1 0 0 (2 7) (0 0) 0.5 4 .0% 8.1 0.0 0.0 0.1 (0 0) 8.2 (3.8) 0.0
PDC dividends (paid) (2.9) (2.7) (2.7) (2.7) Movement in loans 0.0 0.0 0.0 0.0 PDC received/(repaid) 0.3 0.0 12.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 other francing cashflows 0.1 0.1 0.1 0.1 Net cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at YIE 20.3 16.8 17.7 18.4	Gain (loss) on asset disposal Gain(loss) from transfer by absorbtion Net Interest Tazition PDC dividend Other non-operating lems Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Other changes in WC Other non-ash lems Cashflow from operating activities Cashla work from operating activities Capital exponditure (accurate basis) Asset sale proceeds other Investing cash flows	(0.0) 0.0 0.1 0.0 (2.8) (2.8) (2.6) 3.8% 8.2 2.6 (0.8) 2.2 (1.9) 10.3 (5.6) 0.0 (1.9)	0 0 0.0 0.1 0.0 (2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 4.1 (3.7) 0.7 (2.0)	00 01 02 (27) (00) 05 8.1 00 00 00 00 03 (00) 8.4 (14.9) 0.1 (20)	0.0 0.0 0.1 0.0 (2.7) (0.0) 0.0 4.0% 8.1 0.0 0.0 0.0 0.1 (0.0) 8.2 (3.8) 0.0 (1.1)
Movement in loans 0.0 0.0 0.0 0.0 Movement in loans 0.0 0.0 0.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 other financing cashflows 0.1 0.1 0.1 0.1 Not cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at VE 20.3 16.8 17.7 18.4	Gain (loss) on assed disposal Gain(loss) from transfer by absorbtion Net Interest Taxation PDC dividend Other non-operating items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables C	(00) 00 01 00 (28) (28) (28) (28) 28% 82 26 (08) 22 (19) 103 (56) 00 (19) 28	0 00 0 0 0 0 0 0 (2 7) 1 1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 4.1 (3.7) 0.7 (2.0) (0.9)	00 00 (27) (60) 0.5 3.9% 8.1 0.0 0.0 0.3 (0.0) 8.4 (14.9) 0.1 (2.0) (8.4)	0 0 0 0 0 1 0 0 (2 7) (0 0) 0 5 4 0% 8.1 0.0 0.1 (0 0) 8.2 (3.8) 0.0 (1 1) 3.3
PDC received/(repaid) 0.3 0.0 12.0 0.0 Donations received in cash 0.0 0.0 0.0 0.0 other financing cashflows 0.1 0.1 0.1 0.1 0.1 Net cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at Y/E 20.3 16.8 17.7 18.4	Gain (loss) on assed ligocal Gain(loss) from transfer by absorbtion Net Interest Taxation Other on-operating terms Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Change in Current Payables Other on-osen Items Cashidre from operating activities Cashidre from operating activities Nase size proceeds	(0.0) 0.0 0.1 0.0 (2.8) (2.8) (2.9) 3.8% 8.2 2.6 (0.8) 2.6 (0.8) 2.6 (0.8) 2.6 (0.5) (5.6) (0.6) (1.9) 2.8 (0.0)	0 0 0 0 0 1 0 0 (2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 (1.5) 0.0 (2.8) 0.1 (1.5) 0.0 (2.8) 0.1 (1.7) 0.7 (2.7) 0.1 (1.7) 0.7 (2.7) 0.1 (1.7) 0.7 (2.7) 0.1 (1.7) 0.7 (2.7) 0.1 (1.7) 0.7 (2.7) 0.1 (1.7) 0.7 (2.7) 0.1 (1.7) 0.7 (2.9) 0.7 (2.9) 0.7 (2.9) 0.7 (2.9) 0.7 (2.9) 0.7 (2.9) 0.7 (2.9) 0.9 (0.9) 0.7 (0.9) 0.7 (0.9) 0.7 (0.9) 0.7 (0.9) 0.7 (0.9) 0.7 (0.9) 0.9 (0.9) 0.9 (0.9)	0 0 0 0 0 1 0 0 (27) (00) 0.5 3.9% 8.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	00 00 01 00 (27) (00) 0.5 4.0% 8.1 00 00 01 01 01 01 (00) 8.2 (38) 00 (11) (11) 3.3 0.0
Donations received in cash other financing cashflows 0.0 0.0 0.0 Not cash inflow (outflow) 0.1 0.1 0.1 0.1 Not cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at VE Cash and Cash oquivalents at V/E 20.3 16.8 17.7 18.4	Gain (loss) on asset disposal Gain(loss) from transfer by absorbtion Net Interest Taxation Other non-operating items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Cashtow from correcting Cashtow before financing Net Interest PDC dividents (paid) Movement in bans	(00) 00 01 00 (28) (28) (28) (28) 28 (08) 22 (19) (19) (66) (00) (19) 28 (00) (28) 00 (19) 28 (00) (28) 00 (28) 00 (28) 00 (28) 00 (28) (2) (2) (2) (2) (2) (2) (2) (2	0 00 0 0 0 0 0 0 0 2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 (2.1) 0.7 (2.8) 0.1 (3.7) (2.7) (2.8) 0.1 (3.7) (2.7) (2.7) (3.9) (3.7	00 00 01 00 (27) (00) 0.5 3.9% 8.1 00 00 03 (00) 8.4 (14.9) 0.1 (14.9) 0.1 (20) (6.4) 0.0 (27) 0.0	00 00 01 00 (27) (00) 05 4.0% 8.1 00 00 0.1 (00) 8.2 (15) (00) (11) 3.3 00 (27) 0.0
Net cash inflow (outflow) 0.4 (3.5) 0.9 0.7 Cash at V/E 20.3 16.8 17.7 18.4 Cash and cash oquivalents at V/E 20.3 16.8 17.7 18.4	Gain (loss) on asset disposal Gain(loss) from transfer by absorbtion Net Interest Taxation Other non-operating items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Capital expenditure (accurate basis) Asset sale proceeds other Investing cash flows Capital expenditure (accurate basis) PDC dividents (pad) Movement in bans PDC creceive(repaid)	(0.0) 0.0 0.1 0.0 (2.8) (2.6) (2.6) 2.6 (0.8) 2.2 (1.9) 10.3 (5.6) 0.0 (1.9) 2.8 (0.0) (2.8) 0.0 0.3	0 00 0.0 0.1 0.0 (2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.0 (2.8) 0.1 4.1 (3.7) 0.7 (2.0) 0.7 (2.0) 0.0 (0.9) 0.0 (2.7) 0.0 0.0 (2.7) 0.0 0.0 (2.7) 0.0 0.0 (2.7) 0.0 (2.7) 0.0 (2.7) 0.0 (2.7) 0.0 (2.7) 0.0 (2.7) 0.0 (2.7) 0.0 (2.7) 0.0 (2.7) (2.8) (2.7) (2.7) (2.7) (2.8) (2.7) (2.7) (2.7) (2.8) (2.7) (2.7) (2.8) (2.7) (2.7) (2.8) (2.7	00 00 01 00 (27) (0.0) 0.5 3.9% 8.1 0.0 0.0 0.0 0.3 (0.0) 8.4 (14.9) 0.1 (2.0) (6.4) 0.0 (2.7) 0.0 (2.7) 0.0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cash at Y/E 20.3 16.8 17.7 18.4 Cash and Cash equivalents at Y/E 20.3 16.8 17.7 18.4	Gain (loss) on asset disposal Gain(loss) from transfer by absorbtion Net Interest Taxation Other non-operating terms Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Cashfor Yon Operating activities Cashfor Von Core financing Net Interest PDC dividents (paid) Movement in Ioans PDC received(repaid) Donations received in cash	(00) 00 01 00 (28) (28) (28) (28) (28) 28 (08) 22 (19) 100 (19) 28 (00) (19) 28 (00) (28) 00 (19) 28 (00) (28) 00 00 00 00 00 00 00 00 00 0	0 00 0 0 0 0 0 0 0 2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 (2.1) 0.2 (2.8) 0.1 (2.7) 0.2 (2.8) 0.1 (2.7) 0.2 (2.8) 0.1 (2.7) 0.7 (2.7) 0.0 (2.7) 0.7 (2.8) (2.7) 0.7 (2.8) (2.7) (2.7) (2.8) (2.7) (2.7) (2.7) (2.8) (2.7) (2.7) (2.7) (2.7) (2.8) (2.7) (2.7) (2.7) (2.8) (2.7) (2.7) (2.7) (2.8) (2.7) (2.7) (2.7) (2.8) (2.7) (2.7) (2.8) (2.7) (2.7) (2.9) (2.9) (2.7)	00 00 01 00 (27) (00) 0.5 3.9% 8.1 00 0.3 (00) (14) 01 (11) (20) (6.4) 00 (27) 0.0 (27) 0.0 (20) (20)	00 00 01 00 (27) (00) 05 4.0% 8.1 00 00 01 (00) 6.2 (3.2) 00 00 (11) 6.2 (3.2) 00 00 (11) 6.2 (3.3) 00 00 (27) 00 00 00 00 00 00 00 00 00 00 00 00 00
Cash and Cash equivalents at Y/E 20.3 16.8 17.7 18.4	Gain (loss) on asset disposal Gain(loss) con transfer by absorbtion Net interest Taxation PDC dividend Other non-operation items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Cashforw border Genation Net interest PDC dividends (paid) Movement in Joans PDC received (receivad) Donations received in cash other financing cashflows	(0.0) 0.0 0.1 0.0 (2.8) (2.6) (2.6) 2.6 (0.8) 2.2 (1.9) 10.3 (5.6) 0.0 (1.9) (2.8) 0.0 (2.8) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	0 00 0.0 0.0 (2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.0 (2.8) 0.0 (2.8) 0.0 (2.8) 0.1 (3.7) 0.7 (2.0) 0.0 (0.9) 0.0 (0.9) 0.0 0.0 0.0 (2.7) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	00 00 01 00 (27) (0.0) 0.5 8.1 00 00 00 00 00 00 00 00 00 00 00 00 00	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Gain (loss) on asset disposal Gain(loss) con transfer by absorbtion Net interest Taxation PDC dividend Other non-operation items Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Cashforw border Genation Net interest PDC dividends (paid) Movement in Joans PDC received (receivad) Donations received in cash other financing cashflows	(0.0) 0.0 0.1 0.0 (2.8) (2.6) 3.8% 8.2 2.6 (0.8) 2.2 (1.9) 10.3 (5.6) 0.0 (1.9) 2.8 (0.0) (2.8) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	0 00 0.0 0.0 (2.7) 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.0 (2.8) 0.0 (2.8) 0.0 (2.8) 0.1 (3.7) 0.7 (2.0) 0.0 (0.9) 0.0 (0.9) 0.0 0.0 0.0 (2.7) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	00 00 01 00 05 05 81 00 00 00 00 00 03 (00) 84 (149) 01 (20) (84) 01 (27) 00 00 00 00 00 01 (27) 00 00 00 03 00 00 03 00 00 03 00 00 03 00 00	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Gain (loss) on asset disposal Gain(loss) from transfer by absorbtion Net Interest Taxation PDC dividend Other non-operating terms Net Surplus / (Deficit) EBITDA % of Op. revenue EBITDA Change in Current Receivables Change in Current Receivables Cashtow from coreating activities Cashtow from Coreating activities	(00) 00 01 00 (28) (28) (26) 226 (26) 22 (10) 103 (26) (27) (28) (29) (29) (29) (28) (28) (29) (29) (29) (28) (29) (29) (28) (29)	0 00 0.0 0.1 0.1 0.7 3.9% 8.1 (1.5) 0.0 (2.8) 0.1 (3.7) (2.8) 0.1 (3.7) (2.9) 0.1 (3.7) (2.0) (2.7) (0.9) (2.7) (0.9) (2.7) (0.9) (2.7) (0.9) (2.7) (0.9) (2.7) (0.9) (2.7) (0.9) (2.8) (1.1) (1.1) (2.8) (2.8) (2.7) (2.8) (2.7) (2.8) (2.7) (2.9) (2.7) (2.8) (2.7) (2.8) (2.7) (2.9) (2.7) (2.8) (2.7) (2.9) (2.7) (2.8) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (2.9) (2.9) (2.7) (2.9) (2.9) (2.9) (2.7) (2.9) (2.9) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.7) (2.9) (2.9) (2.7) (2.9) (00 00 01 00 (27) (00) 0.5 3.9% 8.1 00 00 03 (00) (14.9) 0.1 (20) (20) (20) (20) (20) (20) (20) (20)	00 00 01 00 (27) (00) 0.5 4.0% 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 (01) (00) (27) 0.0 0.0 (11) 3.3 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.0 0.0 0

23

South Tyneside NHS Foundation Trust	Enc 3
Borrowing Ratios	
Based on year ending 31/03/2013	
Total Revenues Surplus/(Deficit) before Interest Depreciation Revenues available for Debt Service Dividends Paid Total Assets Employed	£216,480,000 £3,763,000 £4,888,000 £8,651,000 -£2,797,000 £99,591,000
Proposed Debt Interest Rate	£9,500,000 2.97%
Term of Borrowing Current Risk Rating 4	10
Debt to Capital Ratio Annual Interest payable Annual Principal repayments Max Annual Debt Service	£9,500,000 £282,150 £950,000 £1,232,150
Ratios: Limits	Proiected Max

Ratios:	Limits	Projected Max
Minimum Dividend Cover (min)	>1	2.99
Minimum Interest Cover (min)	>3	30.66
Minimum Debt Service Cover (min)	>2	7.02
Maximum Debt Service to Revenue (max)	<3%	0.57
Debt/Net assets		10%

South Typeside NHS Foundation Trust





SOUTH TYNESIDE INTEGRATED CARE SERVICES HUB

Financial Summary

1. Introduction

The purpose of this paper is to provide the detail on the prospective cost, both revenue and capital, of the Integrated Care Services Hub.

2. Background

The financial model has been in development for a number of months and has been refined as our understanding of the requirements of the service has improved. Detailed work has been progressed with a wide range of departments including Clinical Services, Estates, Information Technology, Catering, Domestics and other ancillary services.

Detailed feedback has already been received following the Invitation to Submit Outline Solution (ISOS) process which highlighted that our costs were 33% higher than the lowest cost provider. Based upon this intelligence we were able to accurately triangulate our position relative to other bidders and identify the required level of saving to make our bid more competitive.

3. Financial Analysis

3.1 Revenue Costs

The recurrent revenue cost for the model of service we will present within our tender submission is $\pounds 2,699,403$. Appendix B provides a detailed breakdown of the tender price.

These costs can be broken down as:

Bedded Areas	-	£1,530,601
Other Facilities	-	£647,178
Reablement Staffing	-	£521,601

This excludes any contribution to fixed costs as these will be discussed in section 3.3 below and the impact of TUPE cost for the reablement staff.

3.2 Capital Costs

Work progressed by our Estates team in conjunction with Architects and other professional services has identified the capital expenditure requirement for the building.

The model of care team have reviewed our equipment requirements and identified the estimated additional cost in equipping the facility to the necessary specification. This takes the total capital requirement for this development to an estimated £9,500,000.

A key assumption within the financial model is the recovery of capital cost to match the resource consumed. Similar buildings are assumed to have a life of 50 years.

3.3 Contribution to other fixed costs (overheads)

The cost presented in section 3.1 does not include an allowance for a required contribution to fixed cost. This contribution recognises costs such as Finance, Personnel, Learning & Development and Supplies as well as ensuring a rate of return is generated as a contribution to other infrastructure costs incurred in the delivery of this service.

Three options were presented to the Board with associated financial analysis for consideration. As noted in section 2, in order to maximise our score for the price of the bid in comparison with other competitors a maximum overhead of 12.5% was recommended. Whilst this was not expected to enable the Trust to be the lowest cost provider it would, along with other savings identified, provide the maximum assurance that we will evaluate within the 10-20% range thereby increasing the scoring.

It should be noted that we have no control over other bidders price. However, additional Estate requirements including within the final tender may create cost pressure for other bidders which may not have been factored into their ISOS submission.

4. Summary

The capital cost associated with the provision of the South Tyneside Integrated Care Hub is expected to be in the region of £9,500,000.

Based upon the application of a12.5% overhead the total bid price to be included in the final tender on 24 April 2014 is likely to be £3,085,032. This results in a total contribution of £385,629 to the Trust's overheads as detailed below:

Bedded Areas	-	£218,661
Other Facilities	-	£92,454
Reablement Staffing	-	£74,515

Appendix A: Assumptions for ICH Financial Analysis

CAPITAL CO	STS INCLUDING FINANCING:
•	External loan to be secured to fund captial investment of £9,500,000 for a ten year period on an equal installments of principle repayment method Assumed annual interest rate of 2.91% as per interest rate notification April 2014 Annual interest charge included in financial tender over a ten year period Capital investment on build depreciated over the life of the asset assumed at 50 years not the 10 year loan period Capital investment on equipment depreciated over the life of the asset assumed at 10 years No capital costs included for information systems as confirmed by Local Authority
STAFF COS	TS:
•	Staffing costs based on staffing model approved by Executive Director Project Lead Staff costs based on mid-point of proposed integrated care hub pay scale (see separate paper) Staffing model inflated to include cover for - 33 days annual leave - 5 days learning & development - 10 days sickness No overtime allowance included in tender cost No vacancy factor included in tender cost 3% contingency incuded in tender cost for all staff groups except domestics, admin & clerical and handy-person post
OTHER NON	PAY COSTS
•	2% contingency included in tender cost for all revenue operating expenses Services included in tender cost based on a service level agreement with SouthTyneside NHS Foundation Trust: Food preparation and meal production Laundry & Linen Estates maintenance and support VAT at 20% included in tender cost for for services provided to hub by South Tyneside NHS Foundation Trust No costs incuded for Board of Directors

Appendix B: Revenue Cost for ICH Tender

	Residential			Reablement	Reablement	Daycare	
	Beds	Respite	TTT	Staff	Facilities	Facilities	Total
	£	£	£	£	£	£	£
Care Staff							
Care Advocate	263,674	123,048	45,877	229,385	-	-	661,983
Senior Care Advocate	-	-	22,308	111,540	-	-	133,848
Qualified Nurse	173,817	81,115	-	-	-	-	254,932
Total Care Staff	437,491	204,162	68,185	340,925	0	0	1,050,764
Other Staff							
Registered Manager	12,594	5,877	2,650	13,250	-	6,983	41,354
Deputy Managers	4,216	1,967	8,554	42,768	-	0	57,504
Housekeeping	37,883	17,679	7,577	37,883	-	4,062	105,085
Activities Co-ordinator	5,910	2,758	1,182	5,910	-	0	15,761
Admin & Clerical/Reception	18,379	8,577	3,676	18,379	-	24,505	73,515
Handy-person	7,463	3,483	1,570	7,851	-	4,138	24,505
Domestics	51,930	24,234	10,927	54,634	-	28,793	170,519
CAFÉ Facility	-	-	-	-	-	13,843	13,843
Staffing Contingency 3%	14,943	6,973	2,644	-	-	331	24,892
Total Other Staff	153,319	71,549	38,780	180,676	0	82,656	526,979
Premises costs							
Estates Facilities Management & Maintenance	10,068	4,698	2,118	-	10,592	5,582	33,059
Rates	5,757	17,040	7,704	-	38,493	20,250	89,244
Utilities (Water & Sewage & Energy)	11,416	5,327	2,402	-	12,010	6,330	37,484
Building Insurance	2,171	1,013	457	-	2,284	1,204	7,128
Total Premises Costs	29,411	28,078	12,681	0	63,379	33,365	166,915
Other Costs							
Domestic/Window Cleaning - Non Pay	6,091	2,842	1,282	-	6,408	3,377	20,000
Laundry & Linen - SLA Service from STFT (VAT)	4,977	7,058	3,025	-	15,124	-	30,184

SLA with Age UK	-	-	-	-	_	27,000	27,000
Catering SLA Pay (VAT)	24,896	11,618	4,979	-	24,896	5,532	71,922
Catering SLA Non Pay	46,057	21,493	9,211	-	46,057	10,235	133,052
Catering Maintenance	2,243	1,047	449	-	2,243	498	6,480
Business Continuity Insurance	9,752	4,551	2,052	-	10,260	5,407	32,022
Telecoms Maintenance	1,096	512	231	-	1,153	608	3,600
IT PC Equipment	926	432	195	-	974	513	3,040
Other Non Pay - Administration Costs	8,687	4,054	1,828	-	9,139	4,817	28,525
Other Non Pay - WIFI	1,827	853	384	-	1,922	1,013	6,000
Other Non Pay - Staff Uniforms	1,685	786	301	-	1,506	-	4,278
Other cost contingency at 2%	2,587	1,573	692	-	3,458	1,532	9,842
Total Other Costs	110,823	56,819	24,628	0	123,141	60,533	375,945
Capital costs including financing							
Depreciation - STDH New Build	52,380	24,444	11,021	-	55,107	29,043	171,996
Loan Interest & PDC STDH New Build	85,791	40,036	18,051	-	90,257	47,568	281,703
Annual Replacement Cost Equipment	16,200	7,560	3,240	-	16,200	10,800	54,000
Initial Equipment Depreciation	18,811	8,778	3,762	-	18,811	12,540	62,702
Telecoms Equipment Loan & Depreciation	1,031	481	217	-	1,084	571	3,384
Catering Capital Equipment	1,736	810	347	-	1,736	386	5,016
Total Capital Costs	175,948	82,109	36,639	0	183,196	100,908	578,801
TOTAL TENDER VALUE	906,992	442,718	180,913	521,601	369,716	277,462	2,699,403

*This schedule excludes infrastructure contribution and TUPE costs

Appendix 3

South Tyneside NHS Foundation Trust							
Operating Costs as % of Revenues	2010/11 £'000	2011/12 £'000	2012/13 £'000	2010/11 £'000	2011/12 £'000	2012/13 £'000	
Total Revenues	105,304	217,662	217,479				All FTs
Employee Expenses	72,947	155,637	157,724	69.27%	71.50%	72.52%	62.12%
Redundancy & Early Retirement	18	466	3,112	0.02%	0.21%	1.43%	0.31%
R & D	-	27	386	0.00%	0.01%	0.18%	0.53%
Pay Costs	72,965	156,130	161,222	69.29%	71.73%	74.13%	62.96%
Services from NHS Bodies	2,771	14,143	10,309	2.63%	6.50%	4.74%	1.62%
Purchase of healthcare from non NHS bodies	5	-	3	0.00%	0.00%	0.00%	0.78%
Purchase of External Services	2,776	14,143	10,312	2.64%	6.50%	4.74%	2.40%
	7 427	42 555	42.270	7.000/	6 220/	6 4 5 9/	7 5 5 0 /
Supplies and services - clinical (excluding drug costs)	7,437	13,555	13,378	7.06%	6.23%	6.15%	7.55%
Supplies and services - general	1,670	1,854	1,898	1.59%	0.85%	0.87%	1.75%
Inventories consumed (excluding drugs)	-	-	-	0.00%	0.00%	0.00%	0.71%
Drug Costs	4,919	5,823	5,810	4.67%	2.68%	2.67%	7.25%
Supplies and Services	14,026	21,232	21,086	13.32%	9.75%	9.70%	17.26%
Establishment	1,023	3,537	3,526	0.97%	1.62%	1.62%	1.38%
Premises	3,717	7,491	8,678	3.53%	3.44%	3.99%	4.58%
Rentals under operating leases	-	1,446	1,176	0.00%	0.66%	0.54%	0.80%
Loss on Disposal	7	11	43	0.01%	0.01%	0.02%	0.06%
Premises	4,747	12,485	13,423	4.51%	5.74%	6.17%	6.82%
Consultancy costs	326	909	1,017	0.31%	0.42%	0.47%	0.50%
Professional Fees	227	214	860	0.22%	0.10%	0.40%	0.18%
Clinical negligence	1,575	1,724	2,195	1.50%	0.79%	1.01%	1.27%
Professional Costs	2,128	2,847	4,072	2.02%	1.31%	1.87%	1.95%
Provisions & Write Downs	108	24	127	0.10%	0.01%	0.06%	0.11%
Other	463	1,541	1,015	0.10%	0.01%	0.00%	0.00%
Provisions and Other	403 571	1,541 1,565	1,013 1,142	0.44%	0.71% 0.72%	0.47% 0.52%	0.00%
Total Cash OpCosts	97,213	208,402	211,257	92.32%	95.75%	97.14%	93.74%
EBITDA	8,091	9,260	6,222	7.68%	4.25%	2.86%	6.26%
Total Revenues	105,304	217,662	217,479	100.00%	100.00%	100.00%	100.00%
Depreciation	4,321	4,579	4,842	4.10%	2.10%	2.23%	2.70%
Amortisation	19	34	46	0.02%	0.02%	0.02%	0.14%
Impairments	278	130	1,235	0.26%	0.06%	0.57%	1.78%
Net Non-Cash	4,618	4,743	6,123	4.39%	2.18%	2.82%	4.62%
Operating Surplus / Deficit before Financing Costs	3,473	4,517	99	3.30%	2.08%	0.05%	

Appendix 5


31/03/2013

Name of Trust

South Tyneside NHS Foundation Trust

Assumptions

Total Revenues	£217,479,000
Surplus/(Deficit) before Interest Depreciation Revenues available for Debt Service	£99,400 £6,092,000 £6,191,400
Dividends Paid	(£2,776,000)
Total Assets Employed	£99,591,400
Estimated Prudential Borrowing Limit - Tier 1 Estimated Prudential Borrowing Cap - Tier 2 Proposed Debt	£25,775,967 £34,311,224 £9,500,000
Interest Rate	2.01%
Term of Borrowing	10.0
Current Risk Rating	4
Debt to Capital Ratio	
Prudential Borrowing Limit	
Annual Interest payable (year 1) Annual Principal repayments Max Annual Debt Service	
Minimum Dividend Cover (min)	Tier 1 1
Minimum Interest Cover (min)	3
Minimum Debt Service Cover (min)	2
Maximum Debt Service to Revenue (max)	2.5%



Based on year ending

Debt sustainable under individual covenant tests

10.0							r			
4	Estimated PBL Tier 1	Proposed Debt		TIE	ER 1		TIER 2			
	26%	10%	26%	46%	103%	171%	34%	155%	171%	182%
	£25,775,967	£9,500,000	£25,775,967	£45,567,573	£102,624,069	£169,883,447	£34,311,224	£154,256,595	£169,883,593	£181,644,010
	£518,097	£190,950	£518,097	£915,908	£2,062,744	£3,414,657	£689,656	£3,100,558	£3,414,660	£3,651,045
	£2,577,597	£950,000	£2,577,597	£4,556,757	£10,262,407	£16,988,345	£3,431,122	£15,425,659	£16,988,359	£18,164,401
	£3,095,694	£1,140,950	£3,095,694	£5,472,666	£12,325,151	£20,403,002	£4,120,778	£18,526,217	£20,403,020	£21,815,446
Tier 1										
1	2.04	2.16	2.04	1.90	1.49	1.00	1.98	1.11	1.00	0.92
3	11.95	32.42	11.95	6.76	3.00	1.81	8.98	2.00	1.81	1.70
2	2.00	5.43	2.00	1.13	0.50	0.30	1.50	0.33	0.30	0.28
2.5%	1.42%	0.52%	1.40%	2.50%	5.70%	9.40%	1.90%	8.50%	9.40%	10.00%